Anti-CD73 antibodies and uses thereof

By developing monoclonal antibodies or their antigen-binding fragments that specifically bind to CD73, the activity of CD73 enzyme is inhibited and the content of CD73 on the cell surface is reduced, thus solving the problem of immunosuppression caused by adenosine accumulation in the tumor microenvironment and achieving the effects of inhibiting tumor growth and enhancing immunity.

CN118955714APending Publication Date: 2024-11-15PHANES THERAPEUTICS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411072731.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-12-31
Filing Date
2019-03-05
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively inhibit CD73 enzyme activity, leading to the accumulation of adenosine in the tumor microenvironment, which promotes tumor growth and immunosuppression.

Method used

Develop monoclonal antibodies or their antigen-binding fragments that specifically bind to CD73, inhibit the enzymatic activity of CD73, prevent dimerization, induce its internalization, and reduce the content of CD73 on the cell surface.

Benefits of technology

By inhibiting CD73 enzyme activity and reducing CD73 expression on the cell surface, adenosine's immunosuppressive effects can be mitigated, tumor growth can be suppressed, and immune responses can be enhanced, providing a potential means of cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955714A_ABST
    Figure CN118955714A_ABST
Patent Text Reader

Abstract

The present invention describes anti-CD73 antibodies and antigen binding fragments thereof. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of making the antibodies, and methods of using the antibodies to treat or prevent a disease, such as cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application with an application date of March 5, 2019, a national phase entry date of September 9, 2020, an application number of 201980018305.6, and an invention name of “Anti-CD73 antibodies and their uses”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority to U.S. Provisional Application No. 62 / 640,955, filed on March 9, 2018; U.S. Provisional Application No. 62 / 721,044, filed on August 22, 2018; and U.S. Provisional Application No. 62 / 786,598, filed on December 31, 2018. Each disclosure is incorporated herein by reference in its entirety. Field of the Invention

[0004] The present invention relates to monoclonal anti-CD73 antibodies, nucleic acids encoding the antibodies and expression vectors, recombinant cells comprising the vectors, and compositions comprising the antibodies. The present invention also provides methods for preparing the antibodies, and methods for using the antibodies to treat diseases, including cancer and inflammatory diseases, and / or related complications.

[0005] References to electronically submitted sequence listings

[0006] The application contains a sequence listing that was submitted electronically via EFS-Web in an ASCII formatted sequence listing with the file name "689204.10WO Sequence Listing" and a creation date of February 24, 2019, with a size of 114 kb. The sequence listing submitted via EFS-Web is part of this specification and is incorporated herein by reference in its entirety. Background of the Invention

[0008] CD73, also known as ecto-5'-nucleotidase (ecto-5'-NT or EC 3.1.3.5), is a cell surface phosphatase that catalyzes the dephosphorylation of extracellular AMP to generate adenosine. Although it is a glycophosphatidylinositol (GPI) anchored protein, CD73 can also be shed to produce a catalytically active form (Arias et al., J Cell Biol 1997; 136(2): 421-31). Physiologically, hypoxia induces CD73 to control inflammation at the site of injury (Bours et al., Pharmacol Ther 2006; 112: 358-404). Pathologically, CD73 is often found to be overexpressed on regulatory T cells (Tregs) and tumor cells (Paul et al., Trends Immunol 2012; 33: 231-237). Elevated CD73 activity leads to the accumulation of adenosine in the tumor microenvironment (TME).

[0009] There is increasing evidence that CD73 activity at the tumor site is one of the main factors in the formation of a tumor-promoting TME, which is crucial for tumor growth and survival (Whiteside, Expert Rev. Anticancer Ther 2017; 17(6): 527-35). The homeostasis of extracellular ATP adenosine is determined by the activity of CD39 and CD73, where CD39 converts ATP to AMP and CD73 uses AMP to produce adenosine. By binding to adenosine receptors A2a and A2b, adenosine regulates many immune cells to suppress innate and adaptive immunity, including macrophages (Csoka et al., FASEB J 2012; 26: 376-386), dendritic cells (Panther et al., Blood 2003; 101: 3985-3990), natural killer cells (Hausler et al., Cancer Immunotherapy 2011; 60: 1405-1418) and effector T cells (Hoskin et al., Int J Oncol 2008; 32: 527-535). Therefore, it is speculated that the immunosuppression of adenosine can be alleviated by inhibiting the enzymatic activity of CD73 in the TME. Indeed, in vivo animal studies (Jin et al., Cancer Research 2010;70:2245-2255; Stagg et al., Cancer Research 2011;71:2890-2900) have shown that inhibition of CD73 enzymatic activity can inhibit tumor formation and growth, indicating that CD73 is a promising target for cancer therapy. Monoclonal antibodies that inhibit CD73 enzymatic activity and / or reduce the amount of CD73 on the cell surface (i.e., by inducing CD73 internalization) may be effective in treating cancer alone or in combination with other immuno-oncology agents and / or other types of anti-tumor drugs. SUMMARY OF THE INVENTION

[0011] In one general aspect, the invention relates to isolated monoclonal antibodies or antigen-binding fragments thereof that bind CD73.

[0012] The present invention provides an isolated monoclonal antibody or an antigen-binding fragment thereof, which comprises a heavy chain complementary determining region 1 (HCDR1), HCDR2, HCDR3, a light chain complementary determining region 1 (LCDR1), LCDR2 and LCDR3, and each has the following polypeptide sequence:

[0013] (1) SEQ ID NOs: 89, 90, 91, 149, 150 and 151;

[0014] (2) SEQ ID NOs: 41, 42, 43, 101, 102 and 103;

[0015] (3) SEQ ID NOs: 44, 45, 46, 104, 105 and 106;

[0016] (4) SEQ ID NOs: 47, 48, 49, 107, 108 and 109;

[0017] (5) SEQ ID NOs: 50, 51, 52, 110, 111 and 112;

[0018] (6) SEQ ID NOs: 53, 54, 55, 113, 114 and 115;

[0019] (7) SEQ ID NOs: 56, 57, 58, 116, 117 and 118;

[0020] (8) SEQ ID NOs: 59, 60, 61, 119, 120 and 121;

[0021] (9) SEQ ID NOs: 62, 63, 64, 122, 123 and 124;

[0022] (10) SEQ ID NOs: 65, 66, 67, 125, 126 and 127;

[0023] (11) SEQ ID NOs: 68, 69, 70, 128, 129 and 130;

[0024] (12) SEQ ID NOs: 71, 72, 73, 131, 132 and 133;

[0025] (13) SEQ ID NOs: 74, 75, 76, 134, 135 and 136;

[0026] (14) SEQ ID NOs: 77, 78, 79, 137, 138 and 139;

[0027] (15) SEQ ID NOs: 80, 81, 82, 140, 141 and 142;

[0028] (16) SEQ ID NOs: 83, 84, 85, 143, 144 and 145;

[0029] (17) SEQ ID NOs: 86, 87, 88, 146, 147 and 148;

[0030] (18) SEQ ID NOs: 92, 93, 94, 152, 153 and 154;

[0031] (19) SEQ ID NO: 95, 96, 97, 155, 156 and 157; or

[0032] (20) SEQ ID NOs: 98, 99, 100, 158, 159 and 160;

[0033] Wherein, the antibody or antigen-binding fragment thereof specifically binds to CD73, preferably human CD73.

[0034] The present invention provides an isolated monoclonal antibody or an antigen-binding fragment thereof, which comprises a heavy chain complementary determining region 1 (HCDR1), HCDR2, HCDR3, a light chain complementary determining region 1 (LCDR1), LCDR2 and LCDR3, and each has the following polypeptide sequence:

[0035] (1) SEQ ID NOs: 209, 210, 211, 269, 270 and 271;

[0036] (2) SEQ ID NOs: 161, 162, 163, 221, 222 and 223;

[0037] (3) SEQ ID NOs: 164, 165, 166, 224, 225 and 226;

[0038] (4) SEQ ID NOs: 167, 168, 169, 227, 228 and 229;

[0039] (5) SEQ ID NOs: 170, 171, 172, 230, 231 and 232;

[0040] (6) SEQ ID NOs: 173, 174, 175, 233, 234 and 235;

[0041] (7) SEQ ID NOs: 176, 177, 178, 236, 237 and 238;

[0042] (8) SEQ ID NOs: 179, 180, 181, 239, 240 and 241;

[0043] (9) SEQ ID NOs: 182, 183, 184, 242, 243 and 244;

[0044] (10) SEQ ID NOs: 185, 186, 187, 245, 246 and 247;

[0045] (11) SEQ ID NOs: 188, 189, 190, 248, 249 and 250;

[0046] (12) SEQ ID NOs: 191, 192, 193, 251, 252 and 253;

[0047] (13) SEQ ID NOs: 194, 195, 196, 254, 255 and 256;

[0048] (14) SEQ ID NOs: 197, 198, 199, 257, 258 and 259;

[0049] (15) SEQ ID NOs: 200, 201, 202, 260, 261 and 262;

[0050] (16) SEQ ID NOs: 203, 204, 205, 263, 264 and 265;

[0051] (17) SEQ ID NOs: 206, 207, 208, 266, 267 and 268;

[0052] (18) SEQ ID NOs: 212, 213, 214, 272, 273 and 274;

[0053] (19) SEQ ID NOs: 215, 216, 217, 275, 276 and 277; or

[0054] (20) SEQ ID NOs: 218, 219, 220, 278, 279 and 280;

[0055] wherein the antibody or antigen-binding fragment thereof specifically binds to CD73, preferably human CD73.

[0056] In certain embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region whose polypeptide sequence is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:33, 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 35, 37, or 39; or a light chain variable region whose polypeptide sequence is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:34, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36, 38, or 40.

[0057] In certain embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof comprises:

[0058] (a) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 33 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 34;

[0059] (b) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 1 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 2;

[0060] (c) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 3 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 4;

[0061] (d) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 5 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 6;

[0062] (e) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 7 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 8;

[0063] (f) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 9 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 10;

[0064] (g) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 11 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 12;

[0065] (h) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 13 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 14;

[0066] (i) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 15 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 16;

[0067] (j) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 17 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 18;

[0068] (k) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 19 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 20;

[0069] (l) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 21 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 22;

[0070] (m) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 23 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 24;

[0071] (n) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 25 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 26;

[0072] (o) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 27 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 28;

[0073] (p) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 29 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 30;

[0074] (q) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO:31 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO:32;

[0075] (r) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 35 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 36;

[0076] (s) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 37 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 38; or

[0077] (t) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 39 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 40.

[0078] In certain embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof inhibits the enzymatic activity of soluble and / or cell surface CD73.

[0079] In certain embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof prevents dimerization of CD73.

[0080] In certain embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof induces internalization of CD73.

[0081] In certain embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof is chimeric.

[0082] In certain embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof is human or humanized.

[0083] In certain embodiments, the humanized monoclonal antibody or antigen-binding fragment thereof comprises:

[0084] (1) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 286 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0085] The light chain variable region of the polypeptide sequence shown in 293;

[0086] (2) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 282 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0087] The light chain variable region of the polypeptide sequence shown in 290;

[0088] (3) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 282 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0089] The light chain variable region of the polypeptide sequence shown in 291;

[0090] (4) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 282 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0091] The light chain variable region of the polypeptide sequence shown in 292;

[0092] (5) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 283 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0093] The light chain variable region of the polypeptide sequence shown in 290;

[0094] (6) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 283 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0095] The light chain variable region of the polypeptide sequence shown in 291;

[0096] (7) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 283 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0097] The light chain variable region of the polypeptide sequence shown in 292;

[0098] (8) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 284 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0099] The light chain variable region of the polypeptide sequence shown in 290;

[0100] (9) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 284 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0101] The light chain variable region of the polypeptide sequence shown in 291;

[0102] (10) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 284 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0103] The light chain variable region of the polypeptide sequence shown in 292;

[0104] (11) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 285 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0105] The light chain variable region of the polypeptide sequence shown in 290;

[0106] (12) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 285 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0107] The light chain variable region of the polypeptide sequence shown in 291;

[0108] (13) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 285 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0109] The light chain variable region of the polypeptide sequence shown in 292;

[0110] (14) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 283 and a heavy chain variable region having the polypeptide sequence of SEQ ID NO:

[0111] The light chain variable region of the polypeptide sequence shown in 293;

[0112] (15) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 284 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0113] The light chain variable region of the polypeptide sequence shown in 293;

[0114] (16) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 285 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0115] The light chain variable region of the polypeptide sequence shown in 293;

[0116] (17) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 286 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0117] The light chain variable region of the polypeptide sequence shown in 290;

[0118] (18) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 286 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0119] The light chain variable region of the polypeptide sequence shown in 291;

[0120] (19) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 286 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0121] The light chain variable region of the polypeptide sequence shown in 292;

[0122] (20) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 287 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0123] The light chain variable region of the polypeptide sequence shown in 294;

[0124] (21) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 288 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0125] The light chain variable region of the polypeptide sequence shown in 294;

[0126] (22) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 289 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0127] The light chain variable region of the polypeptide sequence shown in 294;

[0128] (23) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 284 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0129] The light chain variable region of the polypeptide sequence shown in 299;

[0130] (24) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 295 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0131] The light chain variable region of the polypeptide sequence shown in 299;

[0132] (25) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 296 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0133] The light chain variable region of the polypeptide sequence shown in 299;

[0134] (26) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 297 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0135] 299; or

[0136] (27) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 298 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0137] The light chain variable region of the polypeptide sequence shown in 299.

[0138] In certain embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof is capable of activating T cells.

[0139] The present invention also provides isolated nucleic acids encoding the monoclonal antibodies or antigen-binding fragments thereof disclosed herein.

[0140] The present invention also provides a vector comprising an isolated nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof of the present invention.

[0141] The present invention also provides a host cell comprising a vector comprising an isolated nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof of the present invention.

[0142] In certain embodiments, a pharmaceutical composition is provided, comprising an isolated monoclonal antibody or antigen-binding fragment thereof of the present invention and a pharmaceutically acceptable carrier.

[0143] The present invention also provides a method of inhibiting the nucleotidase activity of CD73 in a subject in need thereof, comprising administering the pharmaceutical composition of the present invention to the subject.

[0144] The present invention also provides a method of preventing CD73 dimerization in a subject in need thereof, comprising administering a pharmaceutical composition of the present invention to the subject.

[0145] The present invention also provides a method of inducing internalization of CD73 in a subject in need thereof, comprising administering a pharmaceutical composition of the present invention to the subject.

[0146] The present invention also provides a method for treating cancer in a subject in need thereof, comprising administering a pharmaceutical composition of the present invention to a subject. Cancer can be any liquid or solid cancer, for example, it can be selected from but not limited to lung cancer, gastric cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, bladder urothelial carcinoma, metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, head and neck cancer, pancreatic cancer, glioma, glioblastoma and other solid tumors, and non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma (MM), acute myeloid leukemia (AML) and other liquid tumors.

[0147] The present invention also provides a method for producing the monoclonal antibody or antigen-binding fragment thereof of the present invention, comprising culturing a cell containing a nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof under conditions that produce the monoclonal antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof from the cell or culture.

[0148] The present invention also provides a method for preparing a pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment thereof of the present invention, the method comprising combining the monoclonal antibody or antigen-binding fragment thereof with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

[0149] The present invention also provides a method for determining the level of CD73 in a subject. The method comprises (a) obtaining a sample from a subject; (b) contacting the sample with an antibody or antigen-binding fragment thereof of the present invention; (c) determining the level of CD73 in the subject. In certain embodiments, the sample is a tissue sample. The tissue sample can be, for example, a cancer tissue sample. In certain embodiments, the sample is a blood sample.

[0150] The present invention also provides a method for determining the extracellular-5'-nucleotidase activity of CD73 in a subject, wherein the enzymatic activity can be completely inhibited by the monoclonal antibody or antigen-binding fragment thereof of the present invention. The method comprises (a) obtaining a sample from a subject; (b) contacting the sample with the antibody or antigen-binding fragment thereof of the present invention; (c) determining the extracellular-5'-nucleotidase activity of CD73 in the subject. In certain embodiments, the sample is a tissue sample. The tissue sample can be, for example, a cancer tissue sample. In certain embodiments, the sample is a blood sample.

[0151] BRIEF DESCRIPTION OF THE DRAWINGS

[0152] The foregoing summary of the invention, as well as the following detailed description of the preferred embodiments of the application, will be better understood when read in conjunction with the accompanying drawings. It should be understood, however, that the application is not limited to the precise embodiments shown in the drawings.

[0153] Figure 1A and 1B The inhibitory effect of chimeric anti-CD73 mAbs on the nucleotidase activity of human CD73 immobilized on the plate is shown. No antibody, enzyme reaction without added antibody; AMPCP (adenosine 5' (α, β-methylene) diphosphate) was used as a control for inhibition of enzyme activity.

[0154] Figures 2A to 2E The binding of chimeric anti-CD73 mAb to human CD73 in ELISA assay is shown.

[0155] Figure 3 Inhibition of nucleotidase activity of soluble human CD73 by chimeric monoclonal antibodies 60A9A / IgG4 and 39G8A / IgG4 is shown. No mAb, enzyme reaction without added antibody; No CD73, negative control reaction with neither antibody nor CD73.

[0156] Figures 4A to 4DThe binding effect of humanized mAb 60A9-H5L4 / IgG4 on human CD73 and the inhibition of nucleotidase activity of human CD73 are shown. Figure 4A ELISA assay for binding of humanized mAb 60A9-H5L4 / IgG4 to human CD73 is shown; chimeric mAb 60A9-H5L4 / IgG4 was used as a control. Figure 4B The inhibitory effect of humanized mAb 60A9-H5L4 / IgG4 on soluble human CD73 nucleotidase activity is shown. No mAb, enzyme reaction without mAb addition; No CD73, enzyme reaction without CD73 addition. Figure 4C The results show the inhibitory effect of humanized mAb 60A9-H5L4 / IgG4 on the nucleotidase activity of human CD73 expressed on the surface of A375 cells; chimeric mAb 60A9-H5L4 / IgG4 is used as a control. No mAb, enzyme reaction without adding mAb; No AMP, enzyme reaction without adding AMP; No cells, enzyme reaction without adding cells. Figure 4D The inhibitory effects of humanized monoclonal antibodies 60A9-H3L5 / IgG4, 60A9-H5L5 / IgG4, 60A9-H6L5 / IgG4, 60A9-H7L5 / IgG4, 60A9-H8L5 / IgG4 and 60A9-H9L5 / IgG4 on the nucleotidase activity of human CD73 expressed on the surface of A375 cells are shown; chimeric mAb 60A9-H5L4 / IgG4 is used as a control. No mAb, enzyme reaction without adding mAb; No AMP, enzyme reaction without adding AMP; No cells, enzyme reaction without adding cells.

[0157] Figure 5 Shown is the inhibitory effect of humanized anti-CD73 mAb 60A9-H5L4 / IgG4 on CD73 nucleotidase activity in patient serum samples. No mAb, enzyme reaction without added antibody; assay background, enzyme reaction with added 100 μM AMP and 100 μM ATP; cps, counts / second.

[0158] Figure 6 The activation effect of humanized anti-CD73 mAb 60A9-H5L4 / IgG4 on T cell proliferation is shown. DETAILED DESCRIPTION OF THE INVENTION

[0160] Various publications, articles, and patents are cited or described throughout the specification; each of these references is incorporated herein by reference in its entirety. The discussion of documents, acts, materials, devices, articles, etc. included in this specification is intended to provide a background for the present invention. Such discussion is not an admission that all or any of these matters constitute part of the prior art for any invention disclosed or claimed.

[0161] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Otherwise, certain terms used herein have the meanings set forth in the specification.

[0162] It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0163] Unless otherwise indicated, any numerical value, such as a concentration or concentration range described herein, is understood to be modified by the term "about" in any case. Therefore, numerical values ​​generally include ±10% of the value. For example, a concentration of 1 mg / mL includes 0.9 mg / mL to 1.1 mg / mL. Similarly, a concentration range of 1% to 10% (w / v) includes 0.9% (w / v) to 11% (w / v). As used herein, the use of numerical ranges explicitly includes all possible subranges, all individual numerical values ​​within the range, including integers and fractions within the range, unless the context clearly indicates otherwise.

[0164] Unless otherwise indicated, the term "at least" preceding a series of elements should be understood to refer to each element in the series. Using only routine experimentation, those skilled in the art will recognize or be able to ascertain multiple equivalents to the specific embodiments of the invention described herein. The present invention is intended to encompass such equivalents.

[0165] As used herein, the terms "comprises," "comprising," "including," "including," "having," "having," "containing," or "including" or any other variation thereof will be understood to implicitly include the stated integer or group of integers but not to exclude any other integer or group of integers, and to be non-exclusive or open-ended. For example, a composition, mixture, process, method, article, or apparatus that includes a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent in the composition, mixture, process, method, article, or apparatus. In addition, unless expressly indicated to the contrary, "or" refers to an inclusive "or" and not an exclusive "or." For example, any of the following conditions satisfies condition A or B: A is true (or exists) and B is false (or does not exist), A is false (or does not exist) and B is true (or exists), and both A and B are true (or exist).

[0166] As used herein, the connection term "and / or" between multiple referenced elements should be understood to include both individual and combined options. For example, where two elements are connected by "and / or", the first option refers to the application of the first element without the second element. The second option refers to the application of the second element without the first element. The third option refers to the application of the first and second elements together. Any of these options should be understood to fall within the meaning and therefore meet the requirements of the term "and / or" used herein. The parallel application of more than one option should also be understood to be within its meaning and therefore meet the requirements of the term "and / or".

[0167] As used herein, the term "consisting of" or variations such as "composed of" or "consisting of" used throughout the specification and claims means that any stated integer or group of integers is included, but no other integer or group of integers can be added to the specified method, structure or composition.

[0168] As used herein, the term "consisting essentially of, or variations such as "consisting essentially of, or "consisting essentially of, " as used throughout the specification and claims, means including any stated integer or group of integers, and optionally including any stated integer or group of integers that does not materially change the basic or novel property of the specified method, structure, or composition. See MPEP §2111.03.

[0169] As used herein, "subject" refers to any animal, preferably a mammal, most preferably a human. As used herein, the term "mammal" encompasses any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., but more preferably humans.

[0170] The words “right,” “left,” “lower,” and “upper” designate directions in the drawings to which reference is made.

[0171] It should also be understood that when referring to dimensions or characteristics of components of the preferred invention, the terms "approximately," "about," "generally," "substantially," and the like as used herein indicate that the described dimensions / characteristics are not strict boundaries or parameters and do not exclude minor variations thereof that are functionally the same or similar, as understood by those of ordinary skill in the art. At a minimum, such references including numerical parameters will include variations that will not change the least significant digit using mathematical and industrial principles recognized in the art (e.g., rounding, measurement or other systematic errors, manufacturing tolerances, etc.).

[0172] In the context of two or more nucleic acid or polypeptide sequences (e.g., anti-CD73 antibodies and polynucleotides encoding them, CD73 polypeptides and CD73 polynucleotides encoding them), the terms "identical" or percent "identity" means that two or more sequences or subsequences are identical or have a specified percentage of amino acid residues or nucleotides that are identical when compared and aligned for maximum correspondence using one of the following sequence comparison algorithms or by visual inspection.

[0173] To perform sequence comparison, one sequence is typically used as a reference sequence to which the test sequence is compared. When a sequence comparison algorithm is used, the test sequence and the reference sequence are input into a computer, subsequence coordinates are specified if necessary, and sequence algorithm program parameters are specified. The sequence comparison algorithm then calculates the percent sequence identity of the test sequence relative to the reference sequence based on the specified program parameters.

[0174] Optimal alignment of sequences for comparison can be performed, for example, by an algorithm such as the local homology algorithm of Smith and Waterman, Advanced Applied Math, 2:482 (1981), by the homology alignment algorithm of Needleman and Wunsch, J. Molecular Biology, 48:443 (1970), by the similarity search method of Pearson and Lipman, P. Natl. Acad. Sci. USA, 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Genetics Software Package at the Genetics Computer Group at 575 Science Center Madison, Wisconsin), or by visual inspection (see generally, A Laboratory Manual of Molecular Biology, FM Ausubel et al., eds., A Laboratory Manual, a joint venture of Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (1995 Supplement) (Ausubel)).

[0175] Examples of algorithms suitable for determining percentages of sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1990), Journal of Mol. Biol., 215: 403-410 and Altschul et al. (1997), Nucleic Acids Res., 25: 3389-3402, respectively. Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information. The algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short sequences of length W in the query sequence that match or satisfy a positive threshold value T when aligned with a sequence of the same length in the database sequence. T is referred to as the neighborhood sequence score threshold (Altschul et al., supra). These initial neighborhood sequence hits serve as seeds for initiating searches to find longer HSPs containing them. The sequence hits are then extended in both directions in each sequence until the cumulative alignment score no longer increases.

[0176] For nucleotide sequences, the cumulative score is calculated using the parameters M (bonus score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, the cumulative score is calculated using a scoring matrix. Extension of the sequence hits in each direction is stopped when: the cumulative alignment score falls by the value X below its maximum achieved value; the cumulative score becomes zero or lower due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses a word length (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both chains as defaults. For amino acid sequences, the BLASTP program uses a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix as defaults (see Henikoff and Henikoff, Proceedings of the National Academy of Sciences of the United States of America, 89:10915 (1989)).

[0177] In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul, Proceedings of the National Academy of Sciences of the United States of America, 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

[0178] As described below, if the polypeptide encoded by the first nucleic acid cross-reacts immunologically with the polypeptide encoded by the second nucleic acid, it is further indicated that the two nucleic acid sequences or polypeptides are substantially identical. Thus, for example, when two polypeptides differ only by conservative substitutions, it is generally considered that one of the polypeptides is substantially identical to the second polypeptide. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions.

[0179] As used herein, the terms "inhibit," "inhibitory," and "inhibitory effect" refer to reducing an activity, response, symptom, condition, or other biological parameter. This may include, but is not limited to, completely eliminating an activity, response, symptom, or condition. This may also include, for example, a 10% reduction in activity, response, symptom, or condition compared to a natural or control level. Thus, the reduction may be 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any reduction therebetween, compared to a natural or control level. As a non-limiting example, the antibodies of the present invention may inhibit the activity of a CD73 protein. The activity of a CD73 protein may be reduced or eliminated relative to the activity of a natural CD73 protein. As another non-limiting example, the antibodies of the present invention may inhibit or prevent the dimerization of a CD73 protein in a subject. The dimerization of CD73 may be reduced or eliminated relative to natural CD73 dimerization.

[0180] Antibody

[0181] The present invention generally relates to isolated anti-CD73 antibodies, nucleic acids encoding the antibodies and expression vectors, recombinant cells containing the vectors, and compositions containing the antibodies. The present invention also generally relates to methods for preparing the antibodies, and methods for using the antibodies to treat diseases including cancer. The antibodies of the present invention have one or more desired functional properties, including but not limited to high affinity for binding to CD73, high specificity for CD73, the ability to inhibit the nucleotidase activity of CD73, the ability to prevent the dimerization of CD73, the ability to induce the internalization of CD73 into cells, resulting in a decrease in the amount of CD73 on the cell surface, and the ability to inhibit tumor growth in subjects and animal models in need thereof when administered alone or in combination with other anti-cancer therapies.

[0182] In a general aspect, the invention relates to isolated monoclonal antibodies or antigen-binding fragments thereof that specifically bind CD73.

[0183] As used herein, the term "antibody" is used in a broad sense and includes immunoglobulins or antibody molecules, including monoclonal or polyclonal human, humanized, composite and chimeric antibodies and antibody fragments. Generally, antibodies are proteins or peptide chains that show binding specificity to specific antigens. Antibody structure is well known. According to the amino acid sequence of the heavy chain constant domain, immunoglobulins can be divided into five main categories (i.e., IgA, IgD, IgE, IgG and IgM). IgA and IgG are further subclassified into isotypes IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4. Therefore, the antibody of the present invention can be any one of the five main categories or corresponding subcategories. Preferably, the antibody of the present invention is IgG1, IgG2, IgG3 or IgG4. The antibody light chain of a vertebrate species can be designated as one of two significantly different types, i.e., κ and λ, based on the amino acid sequence of its constant domain. Therefore, the antibody of the present invention can include κ or λ light chain constant domains. According to a specific embodiment, the antibody of the present invention includes a heavy chain and / or light chain constant region from a rat or human antibody. In addition to the heavy and light chain constant domains, antibodies also comprise an antigen binding region consisting of a light chain variable region and a heavy chain variable region, both of which comprise three domains (i.e., complementary determining regions 1-3; (CDR1, CDR2, and CDR3)). The light chain variable region domains may alternatively be referred to as LCDR1, LCDR2, and LCDR3, and the heavy chain variable region domains may alternatively be referred to as HCDR1, HCDR2, and HCDR3.

[0184] As used herein, the term "isolated antibody" refers to an antibody that is substantially free of other antibodies with different antigenic specificities (e.g., an isolated antibody that specifically binds to CLDN18.2 is substantially free of antibodies that do not bind to CLDN18.2). In addition, the isolated antibody is substantially free of other cellular material and / or chemicals.

[0185] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, i.e., except for natural mutations that may be present in small amounts, the individual antibodies comprising the population are identical. The monoclonal antibodies of the present invention can be prepared by hybridoma methods, phage display technology, single lymphocyte gene cloning technology or recombinant DNA methods. For example, the monoclonal antibody can be produced by a hybridoma comprising a B cell obtained from a transgenic non-human animal (such as a transgenic mouse or rat) having a genome with a human heavy chain transgene and a light chain transgene.

[0186] As used herein, the term "antigen binding fragment" refers to an antibody fragment, such as a diabody, Fab, Fab', F(ab')2, an Fv fragment, a disulfide-stabilized Fv fragment (dsFv), (dsFv)2, a bispecific dsFv (dsFv-dsFv'), a disulfide-stabilized diabody (dsdiabody), a single-chain antibody molecule (scFv), a single-domain antibody (sdab), a scFv dimer (bivalent diabody), a multispecific antibody formed by a portion of an antibody comprising one or more CDRs, a camelid single-domain antibody, a nanobody, a domain antibody, a bivalent domain antibody, or any other antibody fragment that binds to an antigen but does not contain a complete antibody structure. An antigen binding fragment is capable of binding to the same antigen to which a parent antibody or parent antibody fragment binds. According to specific embodiments, the antigen binding fragment comprises a light chain variable region, a light chain constant region, and an Fd segment of a heavy chain. According to other specific embodiments, the antigen binding fragment comprises Fab and F(ab').

[0187] As used herein, the term "single-chain antibody" refers to a conventional single-chain antibody in the art, which comprises a heavy chain variable region and a light chain variable region connected by a short peptide of about 15 to about 20 amino acids. As used herein, the term "single-domain antibody" refers to a conventional single-domain antibody in the art, which comprises a heavy chain variable region and a heavy chain constant region, or only a heavy chain variable region.

[0188] As used herein, the term "human antibody" refers to an antibody produced by a human or an antibody prepared using any technique known in the art having an amino acid sequence corresponding to an antibody produced by a human. This definition of a human antibody includes complete or full-length antibodies, fragments thereof, and / or antibodies comprising at least one human heavy chain and / or light chain polypeptide.

[0189] As used herein, the term "humanized antibody" refers to a non-human antibody that has been modified to increase sequence homology with a human antibody, thereby retaining the antigen-binding properties of the antibody but reducing its antigenicity in the human body.

[0190] As used herein, the term "chimeric antibody" refers to an antibody in which the amino acid sequence of the immunoglobulin molecule is derived from two or more species. The variable regions of the light and heavy chains generally correspond to the variable regions of antibodies with desired specificity, affinity and performance derived from one mammalian species (e.g., mouse, rat, rabbit, etc.), while the constant regions correspond to sequences of antibodies derived from another mammal (e.g., human) to avoid causing an immune response in that species.

[0191] As used herein, the term "multi-specific antibody" refers to an antibody comprising multiple immunoglobulin variable domain sequences, wherein the first immunoglobulin variable domain sequence in the multiple has binding specificity to the first epitope, and the second immunoglobulin variable domain sequence in the multiple has binding specificity to the second epitope. In one embodiment, the first and second epitopes are on the same antigen, for example, on the same protein (or subunit of a multimeric protein). In one embodiment, the first and second epitopes overlap or substantially overlap. In one embodiment, the first and second epitopes do not overlap or substantially do not overlap. In one embodiment, the first and second epitopes are on different antigens, for example, on different proteins (or different subunits of a multimeric protein). In one embodiment, the multi-specific antibody comprises a third, fourth or fifth immunoglobulin variable domain. In one embodiment, the multi-specific antibody is a bispecific antibody molecule, a tri-specific antibody, or a tetra-specific antibody molecule.

[0192] As used herein, the term "bispecific antibody" refers to a multispecific antibody that binds no more than two epitopes or two antigens. The bispecific antibody is characterized by a first immunoglobulin variable domain sequence with binding specificity to a first epitope and a second immunoglobulin variable domain sequence with binding specificity to a second epitope. In one embodiment, the first and second epitopes are on the same antigen, for example, on the same protein (or subunit of a multimeric protein). In one embodiment, the first and second epitopes overlap or substantially overlap. In one embodiment, the first and second epitopes are on different antigens, for example, on different proteins (or different subunits of a multimeric protein). In one embodiment, the bispecific antibody comprises a heavy chain variable domain sequence and a light chain variable domain sequence with binding specificity to the first epitope and a heavy chain variable domain sequence and a light chain variable domain sequence epitope with binding specificity to the second epitope. In one embodiment, the bispecific antibody comprises a half antibody or fragment thereof with binding specificity to the first epitope and a half antibody or fragment thereof with binding specificity to the second epitope. In one embodiment, the bispecific antibody comprises a scFv or fragment thereof with binding specificity to the first epitope, and a scFv or fragment thereof with binding specificity to the second epitope. In one embodiment, the first epitope is located on CD73, and the second epitope is located on PD-1, PD-L1, TIM-3, LAG-3, CD47, CD3, apelin, claudin 18.2, DLL3, folate receptor α (FRα), TIP-1, CTLA-4, EGFR, HER-2, CD19, CD20, CD33 and / or other tumor-associated immunosuppressants or surface antigens.

[0193] As used herein, the term "CD73" refers to ecto-5'-nucleotidase (ecto-5'-NT or EC 3.1.3.5), a cell surface phosphatase that catalyzes the dephosphorylation of extracellular AMP to produce adenosine. Physiologically, hypoxia induces CD73 to control inflammation at the site of injury (Bours et al., Pharmacol Ther 2006; 112: 358-404). Pathologically, CD73 is often found to be overexpressed on regulatory T cells (Tregs) and tumor cells (Paul et al., Trends Immunol 2012; 33: 231-237). Elevated CD73 activity leads to accumulation of adenosine in the tumor microenvironment (TME). By binding to adenosine receptors A2a and A2b, adenosine regulates many immune cells to suppress innate and adaptive immunity, including macrophages (Csoka et al., FASEB J 2012; 26: 376-386), dendritic cells (Panther et al., Blood 2003; 101: 3985-3990), natural killer cells (Hausler et al., Cancer Immunotherapy 2011; 60: 1405-1418) and effector T cells (Hoskin et al., Int J Oncol 2008; 32: 527-535). Therefore, it is speculated that the immunosuppression of adenosine can be alleviated by inhibiting the enzymatic activity of CD73 in the TME. Indeed, in vivo animal studies (Jin et al., Cancer Research 2010; 70: 2245-2255; Stagg et al., Cancer Research 2011; 71: 2890-2900) have shown that inhibition of the enzymatic activity of CD73 can inhibit tumor formation and growth, indicating that CD73 is a promising target for cancer therapy. The term "human CD73" refers to CD73 derived from humans. An exemplary amino acid sequence of human CD73 is represented in GenBank Accession No. P21589.1 (SEQ ID NO: 281).

[0194] As used herein, an antibody that "specifically binds to CD73" refers to an antibody that binds to CD73, preferably human CD73, with a KD value of 1×10 -7 M or less, preferably 1×10 -8 M or less, more preferably 5×10 -9 M or less, 1×10 -9 M or lower, 5×10 -10 M or less, 1×10 -10 M or less. The term "KD" refers to the dissociation constant, which is obtained from the ratio of Kd to Ka (i.e., Kd / Ka) and is expressed as a molar concentration (M). In view of the present disclosure, the KD value of an antibody can be determined using methods in the art. For example, the KD of an antibody can be determined using surface plasmon resonance, such as by using a biosensor system, such as or by using biolayer interferometry, such as the Octet RED96 system.

[0195] The smaller the KD value of an antibody, the higher the affinity of the antibody for binding to the target antigen.

[0196] According to a specific aspect, the present invention relates to an isolated monoclonal antibody or an antigen-binding fragment thereof, comprising a heavy chain complementary determining region 1 (HCDR1), HCDR2, HCDR3, and a light chain complementary determining region 1 (LCDR1), HCDR2, HCDR3, each having the following polypeptide sequence:

[0197] (1) SEQ ID NOs: 89, 90, 91, 149, 150 and 151;

[0198] (2) SEQ ID NOs: 41, 42, 43, 101, 102 and 103;

[0199] (3) SEQ ID NOs: 44, 45, 46, 104, 105 and 106;

[0200] (4) SEQ ID NOs: 47, 48, 49, 107, 108 and 109;

[0201] (5) SEQ ID NOs: 50, 51, 52, 110, 111 and 112;

[0202] (6) SEQ ID NOs: 53, 54, 55, 113, 114 and 115;

[0203] (7) SEQ ID NOs: 56, 57, 58, 116, 117 and 118;

[0204] (8) SEQ ID NOs: 59, 60, 61, 119, 120 and 121;

[0205] (9) SEQ ID NOs: 62, 63, 64, 122, 123 and 124;

[0206] (10) SEQ ID NOs: 65, 66, 67, 125, 126 and 127;

[0207] (11) SEQ ID NOs: 68, 69, 70, 128, 129 and 130;

[0208] (12) SEQ ID NOs: 71, 72, 73, 131, 132 and 133;

[0209] (13) SEQ ID NOs: 74, 75, 76, 134, 135 and 136;

[0210] (14) SEQ ID NOs: 77, 78, 79, 137, 138 and 139;

[0211] (15) SEQ ID NOs: 80, 81, 82, 140, 141 and 142;

[0212] (16) SEQ ID NOs: 83, 84, 85, 143, 144 and 145;

[0213] (17) SEQ ID NOs: 86, 87, 88, 146, 147 and 148;

[0214] (18) SEQ ID NOs: 92, 93, 94, 152, 153 and 154;

[0215] (19) SEQ ID NO: 95, 96, 97, 155, 156 and 157; or

[0216] (20) SEQ ID NOs: 98, 99, 100, 158, 159 and 160;

[0217] The antibody or antigen-binding fragment thereof specifically binds to CD73, preferably human CD73.

[0218] According to a specific aspect, the present invention relates to an isolated monoclonal antibody or an antigen-binding fragment thereof, comprising a heavy chain complementary determining region 1 (HCDR1), HCDR2, HCDR3, a light chain complementary determining region 1 (LCDR1), LCDR2 and LCDR3, each having the following polypeptide sequence:

[0219] (1) SEQ ID NOs: 209, 210, 211, 269, 270 and 271;

[0220] (2) SEQ ID NOs: 161, 162, 163, 221, 222 and 223;

[0221] (3) SEQ ID NOs: 164, 165, 166, 224, 225 and 226;

[0222] (4) SEQ ID NOs: 167, 168, 169, 227, 228 and 229;

[0223] (5) SEQ ID NOs: 170, 171, 172, 230, 231 and 232;

[0224] (6) SEQ ID NOs: 173, 174, 175, 233, 234 and 235;

[0225] (7) SEQ ID NOs: 176, 177, 178, 236, 237 and 238;

[0226] (8) SEQ ID NOs: 179, 180, 181, 239, 240 and 241;

[0227] (9) SEQ ID NOs: 182, 183, 184, 242, 243 and 244;

[0228] (10) SEQ ID NOs: 185, 186, 187, 245, 246 and 247;

[0229] (11) SEQ ID NOs: 188, 189, 190, 248, 249 and 250;

[0230] (12) SEQ ID NOs: 191, 192, 193, 251, 252 and 253;

[0231] (13) SEQ ID NOs: 194, 195, 196, 254, 255 and 256;

[0232] (14) SEQ ID NOs: 197, 198, 199, 257, 258 and 259;

[0233] (15) SEQ ID NOs: 200, 201, 202, 260, 261 and 262;

[0234] (16) SEQ ID NOs: 203, 204, 205, 263, 264 and 265;

[0235] (17) SEQ ID NOs: 206, 207, 208, 266, 267 and 268;

[0236] (18) SEQ ID NOs: 212, 213, 214, 272, 273 and 274;

[0237] (19) SEQ ID NOs: 215, 216, 217, 275, 276 and 277; or

[0238] (20) SEQ ID NOs: 218, 219, 220, 278, 279 and 280;

[0239] wherein the antibody or antigen-binding fragment thereof specifically binds to CD73, preferably human CD73.

[0240] According to another specific aspect, the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98% or 99% identical to one of SEQ ID NO: 33, 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 35, 37 or 39, or a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98% or 99% identical to one of SEQ ID NO: 34, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36, 38 or 40. According to a preferred embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof according to the present invention comprises a heavy chain variable region comprising a polypeptide sequence having at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: SEQ ID NO: 33, 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 35, 37 or 39, and a light chain variable region comprising a polypeptide sequence having at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 34, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36, 38 or 40, respectively.

[0241] According to another specific aspect, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, comprising:

[0242] (1) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 33 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 34;

[0243] (2) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 1 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 2;

[0244] (3) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 3 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 4;

[0245] (4) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 5 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 6;

[0246] (5) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 7 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 8;

[0247] (6) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 9 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 10;

[0248] (7) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 11 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 12;

[0249] (8) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 13 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 14;

[0250] (9) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 15 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 16;

[0251] (10) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 17 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 18;

[0252] (11) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 19 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 20;

[0253] (12) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 21 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 22;

[0254] (13) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 23 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 24;

[0255] (14) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 25 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 26;

[0256] (15) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 27 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 28;

[0257] (16) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 29 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 30;

[0258] (17) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 31 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 32;

[0259] (18) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 35 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 36;

[0260] (19) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 37 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 38; or

[0261] (20) A heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 39 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 40.

[0262] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 41, 42, 43, 101, 102 and 103, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 1, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 2. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:1, and a light chain variable region having a polypeptide sequence of SEQ ID NO:2.

[0263] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 44, 45, 46, 104, 105 and 106, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 3, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 4. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 3, and a light chain variable region having a polypeptide sequence of SEQ ID NO: 4.

[0264] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 47, 48, 49, 107, 108 and 109, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 5, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 6. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 5, and a light chain variable region having a polypeptide sequence of SEQ ID NO: 6.

[0265] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NO: 50, 51, 52, 110, 111 and 112, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 7, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 8. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 7, and a light chain variable region having a polypeptide sequence of SEQ ID NO: 8.

[0266] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 53, 54, 55, 113, 114 and 115, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 9, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 10. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 9, and a light chain variable region having a polypeptide sequence of SEQ ID NO: 10.

[0267] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 56, 57, 58, 116, 117 and 118, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 11, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 12. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:11, and a light chain variable region having a polypeptide sequence of SEQ ID NO:12.

[0268] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 59, 60, 61, 119, 120 and 121, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 13, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 14. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:13, and a light chain variable region having a polypeptide sequence of SEQ ID NO:14.

[0269] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 62, 63, 64, 122, 123 and 124, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 15, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 16. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:15, and a light chain variable region having a polypeptide sequence of SEQ ID NO:16.

[0270] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 65, 66, 67, 125, 126 and 127, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 17, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 18. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:17, and a light chain variable region having a polypeptide sequence of SEQ ID NO:18.

[0271] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 68, 69, 70, 128, 129 and 130, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 19, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 20. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 19, and a light chain variable region having a polypeptide sequence of SEQ ID NO: 20.

[0272] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 71, 72, 73, 131, 132 and 133, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 21, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 22. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:21, and a light chain variable region having a polypeptide sequence of SEQ ID NO:22.

[0273] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 74, 75, 76, 134, 135 and 136, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 23, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 24. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:23, and a light chain variable region having a polypeptide sequence of SEQ ID NO:24.

[0274] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 77, 78, 79, 137, 138 and 139, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 25, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 26. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:25, and a light chain variable region having a polypeptide sequence of SEQ ID NO:26.

[0275] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 80, 81, 82, 140, 141 and 142, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 27, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 28. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:27, and a light chain variable region having a polypeptide sequence of SEQ ID NO:28.

[0276] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 83, 84, 85, 143, 144 and 145, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 29, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 30. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:29, and a light chain variable region having a polypeptide sequence of SEQ ID NO:30.

[0277] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 86, 87, 88, 146, 147 and 148, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 31, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 32. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:31, and a light chain variable region having a polypeptide sequence of SEQ ID NO:32.

[0278] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 89, 90, 91, 149, 150 and 151, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 33, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 34. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:33, and a light chain variable region having a polypeptide sequence of SEQ ID NO:34.

[0279] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 92, 93, 94, 152, 153 and 154, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 35, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 36. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:35, and a light chain variable region having a polypeptide sequence of SEQ ID NO:36.

[0280] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 95, 96, 97, 155, 156 and 157, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 37, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 38. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:37, and a light chain variable region having a polypeptide sequence of SEQ ID NO:38.

[0281] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 98, 99, 100, 158, 159 and 160, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 39, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 40. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:39, and a light chain variable region having a polypeptide sequence of SEQ ID NO:40.

[0282] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 161, 162, 163, 221, 222 and 223, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 1, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 2. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:1, and a light chain variable region having a polypeptide sequence of SEQ ID NO:2.

[0283] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 164, 165, 166, 224, 225 and 226, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 3, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 4. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:3, and a light chain variable region having a polypeptide sequence of SEQ ID NO:4.

[0284] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 167, 168, 169, 227, 228 and 229, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 5, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 6. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:5, and a light chain variable region having a polypeptide sequence of SEQ ID NO:6.

[0285] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 170, 171, 172, 230, 231 and 232, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 7, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 8. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:7, and a light chain variable region having a polypeptide sequence of SEQ ID NO:8.

[0286] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 173, 174, 175, 233, 234 and 235, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 9, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 10. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:9, and a light chain variable region having a polypeptide sequence of SEQ ID NO:10.

[0287] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 176, 177, 178, 236, 237 and 238, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 11, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 12. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:11, and a light chain variable region having a polypeptide sequence of SEQ ID NO:12.

[0288] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 179, 180, 181, 239, 240 and 241, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 13, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 14. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:13, and a light chain variable region having a polypeptide sequence of SEQ ID NO:14.

[0289] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 182, 183, 184, 242, 243 and 244, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 15, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 16. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:15, and a light chain variable region having a polypeptide sequence of SEQ ID NO:16.

[0290] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 185, 186, 187, 245, 246 and 247, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 17, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 18. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:17, and a light chain variable region having a polypeptide sequence of SEQ ID NO:18.

[0291] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 188, 189, 190, 248, 249 and 250, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 19, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 20. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 19, and a light chain variable region having a polypeptide sequence of SEQ ID NO: 20.

[0292] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 191, 192, 193, 251, 252 and 253, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 21, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 22. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:21, and a light chain variable region having a polypeptide sequence of SEQ ID NO:22.

[0293] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 194, 195, 196, 254, 255 and 256, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 23, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 24. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:23, and a light chain variable region having a polypeptide sequence of SEQ ID NO:24.

[0294] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 197, 198, 199, 257, 258 and 259, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 25, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 26. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:25, and a light chain variable region having a polypeptide sequence of SEQ ID NO:26.

[0295] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 200, 201, 202, 260, 261 and 262, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 27, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 28. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:27, and a light chain variable region having a polypeptide sequence of SEQ ID NO:28.

[0296] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 203, 204, 205, 263, 264 and 265, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 29, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 30. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:29, and a light chain variable region having a polypeptide sequence of SEQ ID NO:30.

[0297] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 206, 207, 208, 266, 267 and 268, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 31, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 32. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:31, and a light chain variable region having a polypeptide sequence of SEQ ID NO:32.

[0298] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 209, 210, 211, 269, 270 and 271, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 33, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 34. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:33, and a light chain variable region having a polypeptide sequence of SEQ ID NO:34.

[0299] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 212, 213, 214, 272, 273 and 274, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 35, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 36. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:35, and a light chain variable region having a polypeptide sequence of SEQ ID NO:36.

[0300] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 215, 216, 217, 275, 276 and 277, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 37, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 38. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:37, and a light chain variable region having a polypeptide sequence of SEQ ID NO:38.

[0301] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences shown in SEQ ID NOs: 218, 219, 220, 278, 279 and 280, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 39, and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher, such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 40. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:39, and a light chain variable region having a polypeptide sequence of SEQ ID NO:40.

[0302] According to another specific aspect, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, wherein the antibody or antigen-binding fragment thereof inhibits the enzymatic activity of soluble and / or cell surface CD73. CD73 is a glycophosphatidylinositol (GPI) protein anchored on the cell surface; it can also be shed to produce a catalytically active form in solution (Arias et al., J Cell Biol 1997; 136 (2): 421-31). Here, cell surface CD73 refers to CD73 on the cell surface anchored by GPI. Soluble CD73 refers to CD73 that is shed from the cell surface and has catalytic activity in solution.

[0303] According to another specific aspect, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, wherein the antibody or antigen-binding fragment thereof prevents the dimerization of CD73. As used herein, "dimerization" refers to the formation of a CD73 dimer by two subunits. Preventing CD73 dimerization refers to blocking or inhibiting the formation of CD73 dimers.

[0304] According to another specific aspect, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, wherein the antibody or antigen-binding fragment thereof induces internalization of CD73. As used herein, "internalization of CD73" refers to the movement of CD73 protein from the cell surface to the interior of the cell.

[0305] According to another specific aspect, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, wherein said antibody or antigen-binding fragment thereof is capable of activating T cells by inhibiting the nucleotidase activity of CD73 and thereby reducing adenosine.

[0306] According to another specific aspect, the present invention relates to the isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, wherein said antibody or antigen-binding fragment thereof is chimeric.

[0307] According to another specific aspect, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, wherein said antibody or antigen-binding fragment thereof is human or humanized.

[0308] According to another specific aspect, the present invention relates to an isolated humanized monoclonal antibody or an antigen-binding fragment thereof, wherein the isolated humanized antibody or an antigen-binding fragment thereof comprises:

[0309] (1) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 286 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 293;

[0310] (2) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 282 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 290;

[0311] (3) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 282 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 291;

[0312] (4) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 282 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 292;

[0313] (5) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 283 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 290;

[0314] (6) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 283 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 291;

[0315] (7) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 283 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 292;

[0316] (8) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 284 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 290;

[0317] (9) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 284 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 291;

[0318] (10) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 284 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 292;

[0319] (11) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 285 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 290;

[0320] (12) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 285 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 291;

[0321] (13) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 285 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 292;

[0322] (14) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 283 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 293;

[0323] (15) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 284 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 293;

[0324] (16) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 285 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 293;

[0325] (17) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 286 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 290;

[0326] (18) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 286 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 291;

[0327] (19) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 286 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 292;

[0328] (20) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 287 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 294;

[0329] (21) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 288 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 294;

[0330] (22) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 289 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 294;

[0331] (23) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 284 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 299;

[0332] (24) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 295 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 299;

[0333] (25) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO: 296 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO: 299;

[0334] (26) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 297 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 299; or

[0335] (27) A heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 298 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 299.

[0336] In one general aspect, the present invention relates to an isolated nucleic acid encoding a monoclonal antibody or an antigen-binding fragment thereof of the present invention. It will be appreciated by those skilled in the art that the coding sequence of a protein can be altered (e.g., replaced, deleted, inserted, etc.) without changing the amino acid sequence of the protein. Therefore, it will be appreciated by those skilled in the art that the nucleic acid sequence encoding the monoclonal antibody or an antigen-binding fragment thereof of the present invention can be altered without changing the amino acid sequence of the protein.

[0337] In another general aspect, the present invention relates to a vector comprising an isolated nucleic acid encoding a monoclonal antibody of the present invention or its antigen-binding fragment. In view of the present disclosure, any vector known to those skilled in the art, such as a plasmid, a cosmid, a phage vector or a viral vector, can be used. In some embodiments, the vector is a recombinant expression vector, such as a plasmid. The vector may include any elements of the conventional functions for constructing an expression vector, such as a promoter, a ribosome binding element, a terminator, an enhancer, a selection marker and an origin of replication. The promoter may be a constitutive, inducible or repressible promoter. It is known in the art that many expression vectors are capable of delivering nucleic acids to cells, which can be used in the present invention for producing antibodies or their antigen-binding fragments in cells. According to embodiments of the present invention, conventional cloning techniques or artificial gene synthesis can be used to produce recombinant expression vectors.

[0338] In another general aspect, the present invention relates to a host cell comprising an isolated nucleic acid encoding a monoclonal antibody of the present invention or its antigen-binding fragment. In view of the present disclosure, any host cell known to those skilled in the art can be used for recombinant expression of the antibody of the present invention or its antigen-binding fragment. In some embodiments, the host cell is an Escherichia coli TG1 or BL21 cell (for expressing, for example, scFv or Fab antibodies), a CHO-DG44 or CHO-K1 cell or a HEK293 cell (for expressing, for example, a full-length IgG antibody). According to a specific embodiment, the recombinant expression vector is transformed into a host cell by conventional methods such as chemical transfection, heat shock or electroporation, and is stably integrated into the host cell genome so that the recombinant nucleic acid is effectively expressed.

[0339] In another general aspect, the present invention relates to a method for preparing a monoclonal antibody or antigen-binding fragment thereof of the present invention, comprising culturing a cell comprising a nucleic acid encoding a monoclonal antibody or antigen-binding fragment thereof under conditions that produce a monoclonal antibody or antigen-binding fragment thereof of the present invention, and recovering the antibody or antigen-binding fragment thereof from the cell or cell culture (e.g., from the supernatant). The expressed antibody or antigen-binding fragment thereof can be harvested from the cell and purified according to conventional techniques known in the art and described herein.

[0340] Pharmaceutical composition

[0341] In another general aspect, the present invention relates to a pharmaceutical composition comprising an isolated monoclonal antibody of the present invention or an antigen-binding fragment thereof and a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutical composition" refers to a product comprising an antibody of the present invention and a pharmaceutically acceptable carrier. The antibodies of the present invention and compositions comprising them can also be used to prepare medicaments for the therapeutic applications mentioned in the present invention.

[0342] As used herein, the term "carrier" refers to any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, oil, lipid, lipid-containing vesicle, microsphere, lipid encapsulation body or other substances known in the art for pharmaceutical preparations. It should be understood that the characteristics of the carrier, excipient or diluent depend on the specific route of administration used. As used herein, the term "pharmaceutically acceptable carrier" refers to a non-toxic substance that does not interfere with the effectiveness of the composition of the present invention or the biological activity of the composition of the present invention. According to a specific embodiment, in view of the present disclosure, any pharmaceutically acceptable carrier suitable for antibody drug compositions can be used in the present invention.

[0343] The formulation of pharmaceutically active ingredients with pharmaceutically acceptable carriers is known in the art, for example, Remington: The Science and Practice of Pharmacy (e.g., 21st edition (2005) and any later editions). Non-limiting examples of other ingredients include: buffers, diluents, solvents, tonicity regulators, preservatives, stabilizers and chelating agents. One or more pharmaceutically acceptable carriers can be used to formulate the pharmaceutical compositions of the present invention.

[0344] In one embodiment of the invention, the pharmaceutical composition is a liquid formulation. A preferred example of a liquid formulation is an aqueous formulation, i.e., a formulation comprising water. The liquid formulation may comprise a solution, a suspension, an emulsion, a microemulsion, a gel, etc. Aqueous formulations typically comprise at least 50% w / w water, or at least 60%, 70%, 75%, 80%, 85%, 90%, or at least 95% w / w water.

[0345] In one embodiment, the pharmaceutical composition can be formulated into an injection that can be injected, for example, by an injection device (e.g., a syringe or an infusion pump). For example, the injection can be delivered subcutaneously, intramuscularly, intraperitoneally, intravitreally or intravenously.

[0346] In another embodiment, the pharmaceutical composition is a solid preparation, such as a freeze-dried or spray-dried composition, which can be used as is, or a solvent and / or diluent can be added thereto by a physician or patient before use. Solid dosage forms can include tablets, such as compressed tablets and / or coated tablets, and capsules (e.g., hard or soft gelatin capsules). The pharmaceutical composition can also be in the form of, for example, a small package, a dragee, a powder, a granule, a lozenge, or a powder for reconstitution.

[0347] Dosage forms may be immediate release, in which case they may contain a water soluble or dispersible carrier, or may be delayed release, sustained release or modified release, in which case they may contain a water-insoluble polymer that modulates the rate of dissolution of the dosage form in the gastrointestinal tract or under the skin.

[0348] In other embodiments, the pharmaceutical composition may be delivered intranasally, intrabuccally, or sublingually.

[0349] In other embodiments, the pharmaceutical composition may be delivered intranasally, intrabuccally, or sublingually.

[0350] The pH in the aqueous formulation may be between pH 3 and pH 10. In one embodiment of the invention, the pH of the formulation is from about 7.0 to about 9.5. In another embodiment of the invention, the pH of the formulation is from about 3.0 to about 7.0.

[0351] In another embodiment of the present invention, the pharmaceutical composition comprises a buffer. The non-limiting examples of buffers include: arginine, aspartic acid, diglycine, citrate, sodium dihydrogen phosphate, fumaric acid, glycine, glycine, histidine, lysine, maleic acid, malic acid, sodium acetate, sodium carbonate, sodium dihydrogen phosphate, sodium phosphate, succinic acid, tartaric acid, trimethylglycine and tris (hydroxymethyl)-aminomethane and mixtures thereof. Buffers can exist alone or in combination at a concentration of about 0.01 mg / ml to about 50 mg / ml, for example, about 0.1 mg / ml to about 20 mg / ml. Pharmaceutical compositions comprising each of these specific buffers constitute alternative embodiments of the present invention.

[0352] In another embodiment of the present invention, the pharmaceutical composition comprises an antiseptic. The non-limiting examples of antiseptic include: benzethonium chloride, benzoic acid, benzyl alcohol, bronopol, butyl 4-hydroxybenzoate, chlorobutanol, chlorocresol, chlorhexidine, chlorphenesin, o-cresol, m-cresol, p-cresol, ethyl 4-hydroxybenzoate, imidazolidinyl urea, methyl 4-hydroxybenzoate, phenol, 2-phenoxyethanol, 2-phenylethanol, propyl 4-hydroxybenzoate, sodium dehydroacetate, thimerosal and mixtures thereof. Antiseptic can exist alone or in combination with a concentration of about 0.01mg / ml to about 50mg / ml, for example, about 0.1mg / ml to about 20mg / ml. The pharmaceutical composition comprising each of these specific antiseptics constitutes an alternative embodiment of the present invention.

[0353] In another embodiment of the present invention, the pharmaceutical composition comprises an isotonic agent. Non-limiting examples of this embodiment include salts (e.g., sodium chloride), amino acids (e.g., glycine, histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, and threonine), sugar alcohols (e.g., glycerol, 1,2-propylene glycol (propylene glycol), 1,3-propylene glycol, and 1,3-butylene glycol), polyethylene glycols (e.g., PEG400) and mixtures thereof. Another example of an isotonic agent includes sugar. Non-limiting examples of sugars may be monosaccharides, disaccharides, or polysaccharides, or water-soluble glucans, including, for example, fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, amylopectin, dextrin, cyclodextrin, α and β-HPCD, soluble starch, hydroxyethyl starch, and sodium carboxymethylcellulose. Another example of an isotonic agent is sugar alcohol, wherein the term "sugar alcohol" is defined as a C (4-8) hydrocarbon having at least one -OH group. The non-limiting examples of sugar alcohols include mannitol, sorbitol, inositol, galactitol, dulcitol, xylitol and arabitol. Isotonic agents can exist alone or in combination at a concentration of about 0.01 mg / ml to about 50 mg / ml, such as about 0.1 mg / ml to about 20 mg / ml. Pharmaceutical compositions comprising each of these specific isotonic agents constitute alternative embodiments of the present invention.

[0354] In another embodiment of the present invention, the pharmaceutical composition comprises a chelating agent. Non-limiting examples of chelating agents include citric acid, aspartic acid, ethylenediaminetetraacetic acid (EDTA) salts and mixtures thereof. Chelating agents can exist alone or in combination at a concentration of about 0.01 mg / ml to about 50 mg / ml, such as about 0.1 mg / ml to about 20 mg / ml. Pharmaceutical compositions comprising each of these specific chelating agents constitute alternative embodiments of the present invention.

[0355] In another embodiment of the present invention, the pharmaceutical composition comprises a stabilizer. Non-limiting examples of stabilizers include one or more aggregation inhibitors, one or more oxidation inhibitors, one or more surfactants and / or one or more protease inhibitors.

[0356] In another embodiment of the present invention, the pharmaceutical composition comprises a stabilizer, wherein the stabilizer is carboxy- / hydroxycellulose and its derivatives (e.g., HPC, HPC-SL, HPC-L, and HPMC), cyclodextrin, 2-methylmercaptoethanol, polyethylene glycol (e.g., PEG 3350), polyvinyl alcohol (PVA), polyvinylpyrrolidone, salts (e.g., sodium chloride), sulfur-containing substances (e.g., thioglycerol), or thioglycolic acid. Stabilizers can exist alone or in combination at a concentration of about 0.01 mg / ml to about 50 mg / ml, e.g., about 0.1 mg / ml to about 20 mg / ml. Pharmaceutical compositions comprising each of these specific stabilizers constitute alternative embodiments of the present invention.

[0357] In other embodiments of the present invention, the pharmaceutical composition comprises one or more surfactants, preferably a surfactant, at least one surfactant, or two different surfactants. The term "surfactant" refers to any molecule or ion consisting of a water-soluble (hydrophilic) part and a fat-soluble (lipophilic) part. Surfactant can be selected from the group consisting of anionic surfactants, cationic surfactants, nonionic surfactants and / or zwitterionic surfactants. Surfactants can exist alone or in combination at a concentration of about 0.1 mg / ml to about 20 mg / ml. Pharmaceutical compositions comprising each of these specific surfactants constitute alternative embodiments of the present invention.

[0358] In another embodiment of the present invention, the pharmaceutical composition comprises one or more protease inhibitors, such as EDTA and / or hydrochloric acid (HCl) benzamidine. The protease inhibitors can be present alone or in combination at a concentration of about 0.1 mg / ml to about 20 mg / ml. Pharmaceutical compositions comprising each of these specific protease inhibitors constitute alternative embodiments of the present invention.

[0359] In another general aspect, the present invention relates to a method for preparing a pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment thereof of the present invention, comprising combining the monoclonal antibody or antigen-binding fragment thereof with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

[0360] How to use

[0361] In another general aspect, the present invention relates to a method of inhibiting the nucleotidase activity of CD73 in a subject in need thereof, the method comprising administering to the subject an isolated monoclonal antibody or antigen-binding fragment thereof of the present invention that specifically binds to CD73, or a pharmaceutical composition of the present invention.

[0362] In another general aspect, the present invention relates to a method of preventing CD73 dimerization in a subject in need thereof, comprising administering to the subject an isolated monoclonal antibody or antigen-binding fragment thereof of the present invention that specifically binds to CD73 or a pharmaceutical composition of the present invention.

[0363] In another general aspect, the present invention relates to a method of inducing CD73 internalization in a subject in need thereof, the method comprising administering to the subject an isolated monoclonal antibody or antigen-binding fragment thereof of the present invention or a pharmaceutical composition of the present invention that specifically binds to CD73. Internalization of CD73 into cells results in a decrease in the amount of CD73 on the cell surface. The amount of CD73 on the cell surface can be measured by methods known in the art, such as immunohistochemistry.

[0364] The functional activity of antibodies and antigen-binding fragments thereof that bind to CD73 can be characterized by methods known in the art and described herein. Cells expressing CD73 can be pre-incubated with the antibody, and then the activity of cell surface CD73 nucleotidase is measured in the presence of the antibody. Methods for characterizing antibodies and antigen-binding fragments thereof that bind to CD73 include, but are not limited to, affinity and specificity assays, including Biacore, ELISA, and OctetRed analysis; the functional activity of anti-CD73 mAbs can also be evaluated in nucleotidase activity assays. According to specific embodiments, methods for characterizing antibodies and antigen-binding fragments thereof that bind to CD73 include those described below.

[0365] In another general aspect, the present invention relates to a method of treating cancer in a subject in need thereof, the method comprising administering to the subject an isolated monoclonal antibody or antigen-binding fragment thereof of the present invention that specifically binds to CD73 or a pharmaceutical composition of the present invention. The cancer may be selected from, but is not limited to, for example: lung cancer, gastric cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, bladder urothelial carcinoma, metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, head and neck cancer, pancreatic cancer, glioma, glioblastoma and other solid tumors, as well as non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma (MM), acute myeloid leukemia (AML) and other liquid tumors.

[0366] In another general aspect, the invention relates to a method of treating an inflammatory disease in a subject in need thereof, the method comprising administering to the subject an isolated monoclonal antibody or antigen-binding fragment thereof of the invention that specifically binds CD73 or a pharmaceutical composition of the invention.

[0367] According to an embodiment of the present invention, the pharmaceutical composition comprises a therapeutically effective amount of an anti-CD73 antibody or an antigen-binding fragment thereof. As used herein, the term "therapeutically effective amount" refers to the amount of an active ingredient or component that induces a desired biological or pharmaceutical response in a subject. Depending on the purpose, the therapeutically effective amount can be determined empirically and conventionally.

[0368] As used herein, for an anti-CD73 antibody or antigen-binding fragment thereof, a therapeutically effective amount refers to an amount of an anti-CD73 antibody or antigen-binding fragment thereof that modulates an immune response in a subject in need thereof. Similarly, as used herein, for an anti-CD73 antibody or antigen-binding fragment thereof, a therapeutically effective amount refers to an amount of an anti-CD73 antibody or antigen-binding fragment thereof that treats a disease, disorder, or symptom; prevents or slows the progression of a disease, disorder, or symptom; or alleviates or completely relieves symptoms associated with a disease, disorder, or symptom.

[0369] According to specific embodiments, the disease, disorder or condition to be treated is cancer, preferably selected from the group consisting of lung cancer, gastric cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, bladder urothelial carcinoma, metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, head and neck cancer, pancreatic cancer, glioma, glioblastoma and other solid tumors, as well as non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma (MM), acute myeloid leukemia (AML) and other liquid tumors. According to other specific embodiments, the disease, disorder or condition to be treated is an inflammatory disease.

[0370] According to a specific embodiment, a therapeutically effective amount refers to a therapeutic amount sufficient to achieve 1, 2, 3, 4 or more of the following effects: (i) reducing or ameliorating the severity of the disease, disorder or symptom to be treated or symptoms associated therewith; (ii) reducing the duration of the disease, disorder or symptom to be treated or symptoms associated therewith; (iii) preventing the development of the disease, disorder or symptom to be treated or symptoms associated therewith; (iv) causing the disease, disorder or symptom to be treated or symptoms associated therewith to regress; (v) preventing the development or onset of the disease, disorder or symptom to be treated or symptoms associated therewith; (vi) preventing (vii) reduce the number of hospitalizations of subjects suffering from the disease, disorder or symptom to be treated, or symptoms related thereto; (viii) reduce the length of hospital stay of subjects suffering from the disease, disorder or symptom to be treated, or symptoms related thereto; (ix) increase the survival rate of subjects suffering from the disease, disorder or symptom to be treated, or symptoms related thereto; (xi) inhibit or alleviate the disease, disorder or symptom to be treated, or symptoms related thereto in a subject; and / or (xii) enhance or improve the prophylactic or therapeutic effect of another therapy.

[0371] The therapeutically effective amount or dose may vary depending on various factors, such as the disease, condition or symptom to be treated, the mode of administration, the target site, the physiological state of the subject (including, for example, age, weight, health status), whether the subject is human or animal, other drugs administered, and whether the treatment is preventive or therapeutic. The therapeutic dose is optimally titrated to optimize safety and efficacy.

[0372] According to a specific embodiment, the compositions described herein are formulated to be suitable for the intended route of administration to a subject. For example, the compositions described herein can be formulated in a form suitable for intravenous, subcutaneous or intramuscular administration.

[0373] As used herein, the terms "treat," "therapeutic," and "therapy" are all intended to refer to improving or reversing at least one measurable physiological parameter associated with cancer and / or inflammatory diseases, disorders, or conditions, which is not necessarily discernible in a subject, but is discernible in a subject. The terms "treat," "therapeutic," and "therapy" may also refer to causing regression of a disease, disorder, or symptom, hindering its progression, or at least slowing its progression. In specific embodiments, "treat," "therapeutic," and "therapy" refer to alleviating, preventing the development or onset of, or reducing the duration of, one or more symptoms associated with a disease, disorder, or symptom (e.g., a tumor, more preferably cancer). In specific embodiments, "treat," "therapeutic," and "therapy" refer to preventing the recurrence of a disease, disorder, or symptom. In specific embodiments, "treat," "therapeutic," and "therapy" refer to increasing the survival rate of a subject suffering from a disease, disorder, or symptom. In specific embodiments, "treat," "therapeutic," and "therapy" refer to curing a subject of a disease, disorder, or symptom.

[0374] According to a specific embodiment, the composition of the present invention is used to treat cancer and / or inflammatory diseases, disorders or conditions. For cancer therapy, it can be used in combination with other therapies, including but not limited to: chemotherapy, anti-CD20 mAb, anti-TIM-3 mAb, anti-LAG-3 mAb, anti-CD47 mAb, anti-apelin mAb, anti-claudin 18.2 mAb, anti-DLL3 mAb, anti-FRα (folate receptor α) mAb, anti-TIP-1 mAb, anti-CTLA-4 antibody, anti-PD-L1 antibody, anti-PD-1 antibody, PD-1 / PD-L1 therapy, other immuno-oncology drugs, anti-angiogenic agents, radiotherapy, antibody-drug conjugates (ADC), targeted therapy or other anti-cancer drugs. Anti-CD73 antibodies can be co-constructed with partner mAbs against the following targets to treat cancers / tumors expressing CD73 and specific tumor-associated antigens: PD-1, PD-L1, LAG3, TIM-3, CTLA-4, EGFR, HER-2, CD19, CD20, CD33, CD47, CD3, apelin, claudin18.2, DLL3, TIP-1, folate receptor α (FRα) and / or other tumor surface antigens.

[0375] As used herein, in the context of applying two or more therapies to a subject, the term "combination" refers to the use of more than one therapy. The term "combination" used does not limit the order of the treatment applied to a subject. For example, applying the first therapy (for example, compositions as described herein) to a subject can be before applying the second therapy (for example, in advance 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks), at the same time, or afterwards (for example, postpone 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks).

[0376] In another general aspect, the invention relates to a method for determining the level of CD73 in a subject. The method comprises (a) obtaining a sample from a subject; (b) contacting the sample with a monoclonal antibody or antigen-binding fragment thereof of the invention; (c) determining the level of CD73 in the subject.

[0377] In another general aspect, the present invention relates to a method for determining the extracellular-5'-nucleotidase activity of CD73 in a subject, wherein the enzymatic activity can be completely inhibited by the monoclonal antibody or antigen-binding fragment thereof of the present invention. The method comprises (a) obtaining a sample from a subject; (b) contacting the sample with an antibody or antigen-binding fragment thereof of the present invention; (c) determining the extracellular-5'-nucleotidase activity of CD73 in the subject.

[0378] As used herein, "sample" refers to a biological sample separated from a subject, which may include, but is not limited to, whole blood, serum, plasma, blood cells, endothelial cells, biopsy tissue (e.g., cancer tissue, liver tissue, etc.), lymph, ascites, tissue fluid, bone marrow, cerebrospinal fluid, saliva, mucus, sputum, sweat, urine, or any other secretion, excretion, or other body fluid. "Blood sample" refers to whole blood or any part thereof, including blood cells, serum, and plasma.

[0379] In certain embodiments, the level of CD73 in a subject may be determined using a method selected from, but not limited to, the following group: Western blot assay, ELISA assay, and / or immunohistochemistry (IHC). Relative protein levels may be determined by Western blot analysis and IHC, and absolute protein levels may be determined by ELISA analysis. When determining the relative level of a CD73 peptide, the level of a CD73 peptide may be determined between at least two samples, for example, between samples from the same subject at different time points, between samples from different tissues of the same subject, and / or between samples from two subjects. Alternatively, when determining the absolute level of a CD73 peptide, for example, by an ELISA assay, the absolute level of a CD73 peptide in a sample may be determined by establishing a standard for the ELISA analysis prior to testing the sample. One skilled in the art will appreciate which analytical technique may be used to determine the level of CD73 in a sample from a subject using the antibodies or antigen-binding fragments thereof of the present invention.

[0380] In certain embodiments, the ecto-5'-nucleotidase activity of CD73 in a subject can be determined using assays known in the art, for example, see Geoghegan et al., MAbs 8:454-67 (2016) and Hay et al., Oncoimmunology Aug. 5(8):e1208875 (2016). One of skill in the art will understand which analytical techniques can be used to determine the ecto-5'-nucleotidase activity of CD73 in a sample from a subject.

[0381] The method of determining the level of CD73 or the level of extracellular-5' nucleotidase activity of CD73 in a sample of a subject can be used to diagnose abnormalities (increased, decreased or insufficient) in the level and / or activity of CD73 in a disease and make appropriate treatment decisions. Such diseases can be selected from, but not limited to, cancer and / or inflammatory diseases. In addition, by monitoring the level and / or activity of CD73 in a subject, the risk of developing the above-mentioned disease can be determined based on the knowledge of the level of CD73 in a specific disease and / or during the progression of a specific disease. Example

[0382] The present invention also provides the following non-limiting embodiments.

[0383] Embodiment 1 is an isolated monoclonal antibody or an antigen-binding fragment thereof, comprising a heavy chain complementary determining region 1 (HCDR1), HCDR2, HCDR3, a light chain complementary determining region 1 (LCDR1), LCDR2 and LCDR3, each having the following polypeptide sequence:

[0384] a. SEQ ID NOs: 89, 90, 91, 149, 150 and 151;

[0385] b. SEQ ID NOs: 41, 42, 43, 101, 102 and 103;

[0386] c. SEQ ID NOs: 44, 45, 46, 104, 105 and 106;

[0387] d. SEQ ID NOs: 47, 48, 49, 107, 108 and 109;

[0388] e. SEQ ID NOs: 50, 51, 52, 110, 111 and 112;

[0389] f. SEQ ID NOs: 53, 54, 55, 113, 114 and 115;

[0390] g. SEQ ID NOs: 56, 57, 58, 116, 117 and 118;

[0391] h. SEQ ID NOs: 59, 60, 61, 119, 120 and 121;

[0392] i. SEQ ID NOs: 62, 63, 64, 122, 123 and 124;

[0393] j. SEQ ID NOs: 65, 66, 67, 125, 126 and 127;

[0394] k. SEQ ID NOs: 68, 69, 70, 128, 129 and 130;

[0395] 1. SEQ ID NOs: 71, 72, 73, 131, 132 and 133;

[0396] m. SEQ ID NOs: 74, 75, 76, 134, 135 and 136;

[0397] n. SEQ ID NOs: 77, 78, 79, 137, 138 and 139;

[0398] o. SEQ ID NOs: 80, 81, 82, 140, 141 and 142;

[0399] p. SEQ ID NO: 83, 84, 85, 143, 144 and 145;

[0400] q. SEQ ID NOs: 86, 87, 88, 146, 147 and 148;

[0401] r. SEQ ID NOs: 92, 93, 94, 152, 153 and 154;

[0402] s. SEQ ID NOs: 95, 96, 97, 155, 156 and 157; or

[0403] t. SEQ ID NOs: 98, 99, 100, 158, 159 and 160;

[0404] Wherein, the antibody or antigen-binding fragment thereof specifically binds to CD73, preferably human CD73.

[0405] Embodiment 2 is an isolated monoclonal antibody or an antigen-binding fragment thereof, which comprises a heavy chain complementary determining region 1 (HCDR1), HCDR2, HCDR3, a light chain complementary determining region 1 (LCDR1), LCDR2 and LCDR3, each having the following polypeptide sequence:

[0406] a. SEQ ID NOs: 209, 210, 211, 269, 270 and 271;

[0407] b. SEQ ID NOs: 161, 162, 163, 221, 222 and 223;

[0408] c. SEQ ID NOs: 164, 165, 166, 224, 225 and 226;

[0409] d. SEQ ID NOs: 167, 168, 169, 227, 228 and 229;

[0410] e. SEQ ID NOs: 170, 171, 172, 230, 231 and 232;

[0411] f. SEQ ID NOs: 173, 174, 175, 233, 234 and 235;

[0412] g. SEQ ID NOs: 176, 177, 178, 236, 237 and 238;

[0413] h. SEQ ID NOs: 179, 180, 181, 239, 240 and 241;

[0414] i. SEQ ID NOs: 182, 183, 184, 242, 243 and 244;

[0415] j. SEQ ID NOs: 185, 186, 187, 245, 246 and 247;

[0416] k. SEQ ID NOs: 188, 189, 190, 248, 249 and 250;

[0417] 1. SEQ ID NOs: 191, 192, 193, 251, 252 and 253;

[0418] m. SEQ ID NOs: 194, 195, 196, 254, 255 and 256;

[0419] n. SEQ ID NO: 197, 198, 199, 257, 258 and 259;

[0420] o. SEQ ID NOs: 200, 201, 202, 260, 261 and 262;

[0421] p. SEQ ID NOs: 203, 204, 205, 263, 264 and 265;

[0422] q. SEQ ID NOs: 206, 207, 208, 266, 267 and 268;

[0423] r. SEQ ID NOs: 212, 213, 214, 272, 273 and 274;

[0424] s. SEQ ID NOs: 215, 216, 217, 275, 276 and 277; or

[0425] t. SEQ ID NOs: 218, 219, 220, 278, 279 and 280;

[0426] Wherein, the antibody or antigen-binding fragment thereof specifically binds to CD73, preferably human CD73.

[0427] Embodiment 3 is an isolated monoclonal antibody or antigen-binding fragment of embodiment 1 or 2, comprising a heavy chain variable region comprising a polypeptide sequence having at least 95% identity to SEQ ID NO: 33, 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 35, 37 or 39, or a light chain variable region comprising a polypeptide sequence having at least 95% identity to SEQ ID NO: 34, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36, 38 or 40.

[0428] Embodiment 4 is the isolated monoclonal antibody or antigen-binding fragment of any one of embodiments 1 to 3, comprising:

[0429] (a) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 33 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 34;

[0430] (b) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 1 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 2;

[0431] (c) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 3 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 4;

[0432] (d) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 5 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 6;

[0433] (e) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 7 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 8;

[0434] (f) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 9 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 10;

[0435] (g) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 11 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 12;

[0436] (h) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 13 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 14;

[0437] (i) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 15 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 16;

[0438] (j) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 17 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 18;

[0439] (k) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 19 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 20;

[0440] (l) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 21 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 22;

[0441] (m) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 23 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 24;

[0442] (n) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 25 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 26;

[0443] (o) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 27 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 28;

[0444] (p) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 29 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 30;

[0445] (q) a heavy chain variable region having the polypeptide sequence set forth in SEQ ID NO:31 and a light chain variable region having the polypeptide sequence set forth in SEQ ID NO:32;

[0446] (r) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 35 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 36;

[0447] (s) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 37 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 38; or

[0448] (t) a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 39 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 40.

[0449] Embodiment 5 is the isolated monoclonal antibody or antigen-binding fragment thereof of any one of embodiments 1 to 4, which inhibits the enzymatic activity of soluble and / or cell surface CD73.

[0450] Embodiment 6 is the isolated monoclonal antibody or antigen-binding fragment thereof of any one of embodiments 1 to 4, wherein the monoclonal antibody or antigen-binding fragment thereof prevents dimerization of CD73.

[0451] Embodiment 7 is the isolated monoclonal antibody or antigen-binding fragment thereof of any one of embodiments 1 to 4, which induces internalization of CD73.

[0452] Embodiment 8 is the isolated monoclonal antibody or antigen-binding fragment thereof of any one of embodiments 1 to 7, wherein the antibody or antigen-binding fragment thereof is chimeric.

[0453] Embodiment 9 is the isolated monoclonal antibody or antigen-binding fragment thereof of any one of embodiments 1 to 8, wherein the antibody or antigen-binding fragment thereof is human or humanized.

[0454] Embodiment 10 is the isolated monoclonal antibody or antigen-binding fragment thereof of any one of embodiments 1 to 9, wherein the antibody or antigen-binding fragment thereof comprises:

[0455] (1) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 286 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0456] The light chain variable region of the polypeptide sequence shown in 293;

[0457] (2) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 282 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0458] The light chain variable region of the polypeptide sequence shown in 290;

[0459] (3) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 282 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0460] The light chain variable region of the polypeptide sequence shown in 291;

[0461] (4) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 282 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0462] The light chain variable region of the polypeptide sequence shown in 292;

[0463] (5) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 283 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0464] The light chain variable region of the polypeptide sequence shown in 290;

[0465] (6) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 283 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0466] The light chain variable region of the polypeptide sequence shown in 291;

[0467] (7) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 283 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0468] The light chain variable region of the polypeptide sequence shown in 292;

[0469] (8) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 284 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0470] The light chain variable region of the polypeptide sequence shown in 290;

[0471] (9) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 284 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0472] The light chain variable region of the polypeptide sequence shown in 291;

[0473] (10) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 284 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0474] The light chain variable region of the polypeptide sequence shown in 292;

[0475] (11) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 285 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0476] The light chain variable region of the polypeptide sequence shown in 290;

[0477] (12) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 285 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0478] The light chain variable region of the polypeptide sequence shown in 291;

[0479] (13) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 285 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0480] The light chain variable region of the polypeptide sequence shown in 292;

[0481] (14) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 283 and a heavy chain variable region having the polypeptide sequence of SEQ ID NO:

[0482] The light chain variable region of the polypeptide sequence shown in 293;

[0483] (15) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 284 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0484] The light chain variable region of the polypeptide sequence shown in 293;

[0485] (16) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 285 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0486] The light chain variable region of the polypeptide sequence shown in 293;

[0487] (17) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 286 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0488] The light chain variable region of the polypeptide sequence shown in 290;

[0489] (18) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 286 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0490] The light chain variable region of the polypeptide sequence shown in 291;

[0491] (19) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 286 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0492] The light chain variable region of the polypeptide sequence shown in 292;

[0493] (20) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 287 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0494] The light chain variable region of the polypeptide sequence shown in 294;

[0495] (21) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 288 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0496] The light chain variable region of the polypeptide sequence shown in 294;

[0497] (22) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 289 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0498] The light chain variable region of the polypeptide sequence shown in 294;

[0499] (23) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 284 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0500] The light chain variable region of the polypeptide sequence shown in 299;

[0501] (24) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 295 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0502] The light chain variable region of the polypeptide sequence shown in 299;

[0503] (25) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 296 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0504] The light chain variable region of the polypeptide sequence shown in 299;

[0505] (26) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 297 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0506] 299; or

[0507] (27) a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 298 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO:

[0508] The light chain variable region of the polypeptide sequence shown in 299.

[0509] Embodiment 11 is the isolated monoclonal antibody or antigen-binding fragment of any one of embodiments 1 to 10, wherein the antibody or antigen-binding fragment thereof is capable of activating T cells.

[0510] Embodiment 12 is an isolated nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof as described in any one of embodiments 1 to 11.

[0511] Embodiment 13 is a vector comprising the isolated nucleic acid described in embodiment 12.

[0512] Embodiment 14 is a host cell comprising the vector described in embodiment 13.

[0513] Embodiment 15 is a pharmaceutical composition comprising the isolated monoclonal antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 11, and a pharmaceutically acceptable carrier.

[0514] Embodiment 16 is a method of inhibiting the nucleotidase activity of CD73 in a subject in need thereof, comprising administering the pharmaceutical composition of embodiment 15 to the subject.

[0515] Embodiment 17 is a method of preventing CD73 dimerization in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 15.

[0516] Embodiment 18 is a method of inducing internalization of CD73 in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 15.

[0517] Embodiment 19 is a method of treating cancer in a subject in need thereof, comprising administering the pharmaceutical composition of embodiment 15 to the subject.

[0518] Embodiment 20 is a method for producing a monoclonal antibody or antigen-binding fragment as described in any one of embodiments 1 to 11, comprising culturing cells containing a nucleic acid encoding a monoclonal antibody or antigen-binding fragment under certain conditions to produce the monoclonal antibody or antigen-binding fragment, and recovering the antibody or antigen-binding fragment from the cells or culture.

[0519] Embodiment 21 is a method for producing a pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment of any one of embodiments 1 to 11, comprising combining the monoclonal antibody or antigen-binding fragment with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

[0520] Embodiment 22 is a method for determining the level of CD73 in a subject, the method comprising:

[0521] a. Obtaining a sample from a subject;

[0522] b. contacting the sample with the isolated monoclonal antibody or antigen-binding fragment thereof of any one of embodiments 1 to 11; and

[0523] c. Determining the level of CD73 in the subject.

[0524] Embodiment 23 is a method as described in embodiment 22, wherein the sample is a tissue sample.

[0525] Embodiment 24 is a method as described in embodiment 23, wherein the tissue sample is a cancer tissue sample.

[0526] Embodiment 25 is a method as described in embodiment 22, wherein the sample is a blood sample.

[0527] Embodiment 26 is a method of determining the ecto-5'-nucleotidase activity of CD73 in a subject, the method comprising:

[0528] a. obtaining a sample from a subject;

[0529] b. contacting the sample with the isolated monoclonal antibody or antigen-binding fragment thereof of any one of embodiments 1 to 11; and

[0530] c. Determining the ecto-5'-nucleotidase activity of CD73 in the subject.

[0531] Embodiment 27 is a method as described in embodiment 26, wherein the sample is a tissue sample.

[0532] Embodiment 28 is a method as described in embodiment 27, wherein the tissue sample is a cancer tissue sample.

[0533] Embodiment 29 is a method as described in embodiment 26, wherein the sample is a blood sample.

[0534] Example

[0535] Example 1: Identification of anti-CD73 monoclonal antibodies

[0536] Mice were immunized with a mixture of human CD73 (huCD73-HIS; containing residues 27-547) and mouse CD73 (mCD73-HIS; containing residues 29-549) fusion proteins, both with a HIS tag at the C-terminus. Plasma titers were determined by ELISA. After euthanasia, spleens and lymph nodes were collected to generate hybridomas. Hybridomas were grown in 384-well tissue culture plates and the supernatants of each well were screened using huCD73-HIS for ELISA and MDA-MB-231 cells for fluorescence activated cell sorting (FACS). Positive clones were further analyzed by nucleotidase activity assay and fixed to the plate. The top positive clones showing inhibition of nucleotidase activity were isolated and sequenced.

[0537] Tables 1 and 2 provide the sequences of the heavy and light chain variable regions of the anti-CD73 monoclonal antibodies, and Tables 3 to 6 provide the CDR regions of the anti-CD73 monoclonal antibodies.

[0538] Table 1: Heavy chain variable region sequences of anti-CD73 mAbs

[0539]

[0540]

[0541]

[0542] VH: heavy chain variable region

[0543] Table 2: Light chain variable region sequences of anti-CD73 mAbs

[0544]

[0545]

[0546] VL: light chain variable region

[0547] Table 3: Heavy chain CDR regions 1 to 3 of anti-CD73 mAbs

[0548]

[0549]

[0550] HC: heavy chain; CDR: complementarity determining region; ID: sequence number

[0551] The HC CDRs of anti-CD73 mAb were determined using the IMGT method (Lefranc, M.-P. et al., Nucleic Acids Res., 1999; 27: 209-212).

[0552] Table 4: Light Chain CDR Regions 1-3 of Anti-CD73 mAbs

[0553]

[0554]

[0555] LC: light chain; CDR: complementarity determining region

[0556] The LC CDRs of anti-CD73 mAb were determined using the IMGT method (Lefranc, M.-P. et al., Nucleic Acids Res., 1999; 27: 209-212).

[0557] Table 5: Heavy chain CDR regions 1 to 3 of anti-CD73 mAbs

[0558]

[0559]

[0560] HC: heavy chain; CDR: complementarity determining region

[0561] The HC CDRs of anti-CD73 mAbs were determined using a combination of the methods of IMGT ((Lefranc, M.-P. et al., Nucleic Acids Research, 1999; 27: 209-212) and Kabat (Elvin A. Kabat et al., Protein Sequences of Immunological Significance, 5th Edition (1991)).

[0562] Table 6: Light Chain CDR Regions 1 to 3 of Anti-CD73 mAbs

[0563] mAb LC CDR1 ID LC CDR2 ID LC CDR3 ID 37C7A RSSQNLVHSYGNTYLH 221 KVSNRFS 222 SQNTHVPWT 223 38C16A KSSQSLLDSDGRTYLN 224 LVSKLDS 225 WQGTHFPHT 226 39G8A KSSQSLLNSSNQKNYLA 227 FASTRES 228 QQHYSTPYT 229 43E8A RASESVDNYGISFMN 230 AASNQGS 231 QQSKEVPFT 232 46J3A RASKNISKYLA 233 SGSTLQS 234 QQHNEYPFT 235 46O19A KSSQSLLNSGNQKNYLT 236 WASTRES 237 QNDYSYPLT 238 47H24A RASQDIGSRLT 239 ATSSLDS 240 LQYASSPFT 241 49O5A EASDHIDNWLA 242 GATSLET 243 QQYWSSPFT 244 50B10A RASQDISNYLN 245 YTSRLHS 246 QQGNTLPWT 247 50H17A KSSQSLLNSGNQKNYLT 248 WASTRES 249 QNDYSYPLT 250 50E16A KASQDVGTAVA 251 WASTRHT 252 QQYSSYPYT 253 50F1A KSSQSLLNSGNQKNYLT 254 WASTRES 255 QNDYSYPLT 256 54I14A RASENIYSYFA 257 NAKTLAE 258 QHHYGTPFT 259 52K11A SSNKSLLHSNDITYLY 260 RMSNLAS 261 AQMLERPWT 262 53H21A SASSSVSYMY 263 LTSNLAS 264 QQWSSNPWT 265 53I12A SASQGISNYLN 266 YTSSLHS 267 QQYSKLPRT 268 60A9A KSSQSLLNSSNQKNYLA 269 FASTRDS 270 QQHYSTPLT 271 39J9A RASENIYYSLA 272 NADTLED 273 KQAYDVPLT 274 49H8A SASSSVSYMY 275 LTSNLAS 276 QQWSSNPPT 277 51B10A KASQDINSYLS 278 RANRLVD 279 LQYDEFPLT 280

[0564] LC: light chain; CDR: complementarity determining region

[0565] The LC CDRs of anti-CD73 mAbs were determined using a combination of the methods of IMGT ((Lefranc, M.-P. et al., Nucleic Acids Research, 1999; 27: 209-212) and Kabat (Elvin A. Kabat et al., Protein Sequences of Immunological Significance, 5th Edition (1991)).

[0566] Example 2: Production and purification of mAbs from culture medium of transfected 293E cells

[0567] To obtain recombinant anti-CD73 chimeric mAbs, expression vectors containing mouse variable regions (VH and VL) fused to the constant regions of human IgG1 heavy and kappa light chains with LALA mutations (L234A / L235A), respectively, were transiently transfected into 293E cells. Recombinant antibodies produced from 293E cell suspensions were purified by protein A affinity chromatography.

[0568] Example 3: Purified anti-CD73 chimeric monoclonal antibody inhibits nucleotidase activity of immobilized CD73

[0569] HIS-tagged human CD73 (huCD73-HIS, 60 μL / well, 0.15 μg / mL) in assay buffer (25 mM Tris-HCl, pH 7.5 and 5 mM MgCl2) was coated on nickel-plated plates (Thermo Fisher Scientific, catalog number: 15242) overnight at 4°C. After washing, anti-CD73 chimeric mAb was added and incubated at room temperature for 1 hour. The enzymatic reaction for measuring CD73 nucleotidase activity was initiated by adding 100 μM AMP to the plate. The reaction was carried out at 37°C for 20 minutes. Free phosphate was detected and quantified by the malachite green phosphate detection kit (R&D Systems, catalog number: DY996). The inhibitory effect of anti-CD73 chimeric mAb on the nucleotidase activity of immobilized CD73 is shown in Figure 1A and 1B Enzyme reaction without antibody and inhibitor; AMPCP (adenosine 5'(α,β-methylene) diphosphate) was used as a control for inhibition of enzyme activity.

[0570] Example 4: ELISA binding assay of chimeric mAb

[0571] Human CD73 with a HIS tag (huCD73-HIS, 50 μL / well, at a concentration of 5 μg / mL (85 nM)) (BPS Bioscience, catalog number 71184) in carbonate coating buffer was coated on an ELISA plate overnight at 4°C. After washing with TBST buffer (TBS buffer containing 0.05% Tween 20), the ELISA plate was blocked with 5% BSA in TBST for 1 hour at room temperature and then washed again. Chimeric anti-CD73 antibody was added, mixed and incubated at room temperature for 1 hour. The plate was washed and the binding of the anti-CD73 antibody to the immobilized huCD73-HIS was detected by adding anti-human IgG (anti-hIgG-HRP) conjugated to horseradish peroxidase (Thermo Fisher, catalog number: H10007) and incubating for 1 hour. The plate was washed and the ELISA was developed using a one-step detection solution (Thermo Fisher, catalog number: 34029) and the absorbance at 450 nm was measured. The results of anti-CD73 mAb binding to CD73 are shown in Figures 2A to 2E shown.

[0572] Example 5: Anti-CD73 mAb inhibits nucleotidase activity of soluble CD73

[0573] The assay was performed using recombinant human CD73 in solution rather than fixed on a plate. The final concentration of human CD73 with a HIS tag (huCD73-HIS) (BPS Bioscience, catalog number: 71184) was 0.5 nM, and various concentrations of anti-CD73 antibodies were incubated in assay buffer (25 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 140 mM NaCl, and 0.1% BSA) at 37°C for 20 minutes. AMP (Sigma Aldrich, catalog number: A2252) was added to a final concentration of 400 μM. After the plate was incubated at 37°C for 20 minutes, it was detected with a malachite green phosphate detection kit (R&D Systems, catalog number: DY996). Two chimeric anti-CD73 mAbs, 60A9-H5L4 / IgG4 and 39G8A / IgG4, were made by fusing the VH and VL regions of mouse mAbs 60A9A and 39G8A to the constant regions of human IgG4 heavy chain and kappa light chain, respectively. The chimeric antibodies were expressed in CHO cells, purified by protein A affinity chromatography and tested in this assay. The experimental results of 60A9-H5L4 / IgG4 and 39G8A / IgG4 inhibiting the nucleotidase activity of soluble CD73 are shown in Figure 3 shown.

[0574] Example 6: Humanization of anti-CD73 monoclonal antibody

[0575] Mouse anti-CD73 monoclonal antibodies 60A9A and 39G8A were humanized to reduce the immunogenic potential when used in human patients. The sequences of the heavy and light chain variable regions (VH and VL) were compared with human antibody sequences in the Protein Data Bank (PDB) database, and a homology model was established. The CDRs in the heavy and light chains of the mouse mAb were transplanted into a human framework that is most likely to maintain the appropriate structure required for antigen binding. Tables 7 and 8 show the sequences of the humanized VH and VL regions.

[0576] The humanized VH and VL regions were fused to the constant regions of human IgG1 heavy chain and kappa light chain with LALA mutation (L234A / L235A), respectively. The construct corresponding to the mAb sequence was used for transient transfection in 293E cells, and the humanized mAb was purified using protein A chromatography. The humanized mAb was detected in an enzyme activity assay by soluble human CD73. In this experiment, 0.4nM huCD73 was first incubated with mAb on ice for 1 hour, and then AMP was added to a final concentration of 100μM to initiate the enzyme reaction. Table 9 shows the IC50 values ​​of the humanized monoclonal antibodies.

[0577] Humanized mAb 60A9-H5L4 on a human IgG4 / κ backbone (60A9-H5L4 / IgG4) was analyzed by ELISA binding assay; an IgG4 chimeric form of 60A9A (60A9-H5L4 / IgG4) was used as a control. Figure 4A As shown. Under the conditions of Example 5, the ability of 60A9-H5L4 / IgG4 to inhibit the nucleotidase activity of soluble CD73 was analyzed. The results are shown in Figure 4B shown.

[0578] Table 7: Humanized heavy chain variable region sequences of anti-CD73 mAbs

[0579]

[0580]

[0581] Table 8: Humanized light chain variable region sequences of anti-CD73 mAbs

[0582]

[0583] Table 9: IC50 values ​​of humanized monoclonal antibodies determined by huCD73 enzymatic assay in solution

[0584]

[0585]

[0586] The name 60A9-H1L1 indicates the mAb constructed using VH 60A9-H1 and VL 60A9-L1. All other humanized monoclonal antibodies use the same naming convention.

[0587] Example 7: Anti-CD73 mAb inhibits nucleotidase activity of cell surface CD73

[0588] A375 cells were collected with PBS-EDTA (2mM EDTA in PBS) and washed twice in PBS buffer supplemented with 0.1% BSA. 100,000 cells were plated in the presence of various concentrations of anti-CD73 antibodies and incubated at 37°C for 20 minutes. AMP was then added to a final concentration of 125μM (Sigma-Aldrich, catalog number: A2252) in a final volume of 60μL, and the reaction was kept at 37°C for 60 minutes. The plate was then centrifuged and 40μL of the supernatant was transferred to a new plate. ATP (Sigma-Aldrich, catalog number: A9187) was added to a final concentration of 100μM in a final volume of 50μL, and the mixture was incubated at 37°C for 15 minutes. Added in a 1:1 ratio 2.0 reagent (Promega, catalog number: G9242) was used to determine the AMP level in the mixture and to calculate the enzyme activity in a given reaction based on the AMP concentration at the end of the reaction. The results of inhibition of CD73 activity by humanized anti-CD73 mAb (on a human IgG1 LALA / κ backbone) in a cell-based assay are shown in Table 10.

[0589] Humanized anti-CD73 mAbs 60A9-H5L4 / IgG4, 60A9-H3L5 / IgG4, 60A9-H5L5 / IgG4, 60A9-H6L5 / IgG4, 60A9-H7L5 / IgG4, 60A9-H8L5 / IgG4, and 60A9-H9L5 / IgG4 were tested in a cell-based phosphate detection method. In this assay, 50,000 A375 cells were washed and plated in assay buffer (25mMTris-HCl, pH7.5, 5mM MgCl2, 140mM NaCl, and 0.1% BSA). The final AMP concentration of the enzyme reaction was 400μM and lasted for 20 minutes at 37°C. The free phosphate produced by AMP hydrolysis was quantified using the Malachite Green Phosphate Assay Kit (R&D Systems, catalog number: DY996). The assay results are shown in Figure 2. Figure 4C and 4D shown.

[0590] Table 10: IC50 values ​​of humanized monoclonal antibodies in cell-based CD73 activity assay

[0591]

[0592]

[0593] Example 8: Anti-CD73 mAb inhibits nucleotidase activity of CD73 in patient serum samples

[0594] Serum samples from patients with colorectal cancer were used to evaluate the inhibitory activity of humanized anti-CD73 mAb 60A9-H5L4 / IgG4. 20 μL of serum and 10 μL of anti-CD73 mAb in PBS buffer supplemented with 0.1% BSA were incubated at 37°C for 30 minutes. 10 μL of 500 μM AMP (Sigma-Aldrich, catalog number: A2252) was added, and the reaction mixture was incubated at 37°C for 30 minutes. ATP (Sigma-Aldrich, catalog number: A9187) was then added to a final concentration of 100 μM. 25 μL of the reaction mixture was transferred to a white half-area 96-well plate. 2.0 reagent (Promega, catalog number: G9242) was added to the mixture and its residual AMP content was determined by measuring its inhibition of ATP detection. Samples containing 100 μM AMP and 100 μM ATP were used to establish the assay background, and samples containing only 100 μM ATP were used as positive controls.

[0595] The inhibitory effect of humanized anti-CD73 mAb 60A9-H5L4 / IgG4 on the nuclease activity of CD73 in patient serum samples was analyzed at 1000 nM. Figure 5 shown.

[0596] Example 9: Humanized anti-CD73 mAb 60A9-H5L4 / IgG4 activates T cell proliferation

[0597] Primary human CD4+ T cells were isolated from frozen peripheral blood mononuclear cells using the CD4+ T cell isolation kit (Miltenyi Biotec, catalog number: 130-096-533). The isolated CD4+ T cells were isolated at a density of 1,000,000 cells per ml in DPBS and cultured using CellTrace TMCFSE cell proliferation kit (Invitrogen, catalog number: C34554) labeling, 37 ° C for 30 minutes. The cells were washed 3 times with cold DPBS and resuspended in AIM V medium (Gibco, catalog number: 12055083). 100,000 cells per well were pre-incubated with various concentrations of 60A9-H5L4 / IgG4 at 37 ° C for 1 hour. T cells were activated by adding T cell activators to a final concentration of 60 IU / mL, which were Dynabeads human T-activators CD3 / CD28 (Gibco, catalog number: 11131D) and human IL-2 with a microsphere to cell ratio of 1: 1. Subsequently, AMP (Sigma Aldrich, catalog number: A2252) was added to a final concentration of 100 μM. After incubation at 37°C for 72 hours, cells were stained with PE / Cy7 anti-human CD4 antibody (BioLegend, catalog number: 357409). Both PE / Cy7 and CFSE signals were analyzed by AttuneNxT flow cytometer. For the measurement window, CFSE CD4+ cells in the absence of T cell activation reagent did not undergo cell division, so it was used to define the baseline; while in the absence of AMP, activated CFSE CD4+ cells (treated with T cell activators) underwent uninhibited cell division, so it was used to define the maximum proliferation. The activation effect of 60A9-H5L4 / IgG4 on T cell proliferation is shown in Figure 6 Cells treated with AMP were inhibited as expected, likely due to the production of cell surface CD73 adenosine, and the addition of 75 nM anti-CD73 mAb 60A9-H5L4 / IgG4 activated the cells, indicating that this mAb has functional activity for T cell activation.

[0598] Those skilled in the art will recognize that the above embodiments may be modified without departing from the broad inventive concept of the present invention. Therefore, it should be understood that the present invention is not limited to the specific embodiments disclosed, but is intended to cover modifications within the spirit and scope of the present invention as defined in this specification.

Claims

1. An isolated monoclonal antibody or antigen-binding fragment thereof, comprising heavy chain complementary determining region 1 (HCDR1), HCDR2, HCDR3, light chain complementary determining region 1 (LCDR1), LCDR2 and LCDR3, each having the following polypeptide sequence: a. SEQ ID NOs: 89, 90, 91, 149, 150 and 151, or SEQ ID NOs: 209, 210, 211, 269, 270 and 271; b.SEQ ID NO: 41, 42, 43, 101, 102 and 103, SEQ ID NO: 161, 162, 163, 221, 222 and 223 or; c. SEQ ID NOs: 44, 45, 46, 104, 105 and 106, or SEQ ID NOs: 164, 165, 166, 224, 225 and 226; d. SEQ ID NOs: 47, 48, 49, 107, 108 and 109, or SEQ ID NOs: 167, 168, 169, 227, 228 and 229; e. SEQ ID NOs: 50, 51, 52, 110, 111 and 112, or SEQ ID NOs: 170, 171, 172, 230, 231 and 232; f. SEQ ID NOs: 53, 54, 55, 113, 114 and 115, or SEQ ID NOs: 173, 174, 175, 233, 234 and 235; g. SEQ ID NOs: 56, 57, 58, 116, 117 and 118, or SEQ ID NOs: 176, 177, 178, 236, 237 and 238; h. SEQ ID NOs: 59, 60, 61, 119, 120 and 121, or SEQ ID NOs: 179, 180, 181, 239, 240 and 241; i. SEQ ID NOs: 62, 63, 64, 122, 123 and 124, or SEQ ID NOs: 182, 183, 184, 242, 243 and 244; j. SEQ ID NOs: 65, 66, 67, 125, 126 and 127, or SEQ ID NOs: 185, 186, 187, 245, 246 and 247; k. SEQ ID NOs: 68, 69, 70, 128, 129 and 130, or SEQ ID NOs: 188, 189, 190, 248, 249 and 250; 1. SEQ ID NOs: 71, 72, 73, 131, 132 and 133, or SEQ ID NOs: 191, 192, 193, 251, 252 and 253; m. SEQ ID NOs: 74, 75, 76, 134, 135 and 136, or SEQ ID NOs: 194, 195, 196, 254, 255 and 256; n. SEQ ID NOs: 77, 78, 79, 137, 138 and 139, or SEQ ID NOs: 197, 198, 199, 257, 258 and 259; o. SEQ ID NOs: 80, 81, 82, 140, 141 and 142, or SEQ ID NOs: 200, 201, 202, 260, 261 and 262; p. SEQ ID NOs: 83, 84, 85, 143, 144 and 145, or SEQ ID NOs: 203, 204, 205, 263, 264 and 265; q. SEQ ID NOs: 86, 87, 88, 146, 147 and 148, or SEQ ID NOs: 206, 207, 208, 266, 267 and 268; r. SEQ ID NOs: 92, 93, 94, 152, 153 and 154, or SEQ ID NOs: 212, 213, 214, 272, 273 and 274; s. SEQ ID NOs: 95, 96, 97, 155, 156 and 157, or SEQ ID NOs: 215, 216, 217, 275, 276 and 277; or t. SEQ ID NO: 98, 99, 100, 158, 159 and 160, or SEQ ID NO: 218, 219, 220, 278, 279 and 280; in, The antibody or antigen-binding fragment thereof specifically binds to CD73, preferably human CD73.

2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain variable region or a light chain variable region, wherein the heavy chain variable region comprises a polypeptide sequence having at least 95% identity to SEQ ID NO: 286, 33, 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 35, 37, 39, 282, 283, 284, 285, 287, 288, 289, 295, 296, 297, or 298, and the light ... NO: 293, 34, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36, 38, 40, 290, 291, 292, 294 or 299 has a polypeptide sequence that is at least 95% identical.

3. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 or 2, include: a. a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 286 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 293; b. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 33 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 34; c. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 1 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 2; d. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 3 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 4; e. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 5 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 6; f. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 7 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 8; g. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 9 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 10; h. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 11 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 12; i. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 13 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 14; j. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 15 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 16; k. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 17 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 18; 1. A heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 19 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 20; m. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 21 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 22; n. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 23 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 24; o. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 25 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 26; p. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 27 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 28; q. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 29 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 30; r. A heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 31 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: The light chain variable region of the polypeptide sequence shown in 32; s. A heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 35 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: The light chain variable region of the polypeptide sequence shown in 36; t. A heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 37 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: The light chain variable region of the polypeptide sequence shown in 38; u. A heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 39 and a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: The light chain variable region of the polypeptide sequence shown in 40; v. a heavy chain variable region having the polypeptide sequence shown in 282 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 290; w. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 282 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 291; x. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 282 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 292; y. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 283 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 290; z. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 283 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 291; aa. A heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 283 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 292; bb. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 284 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 290; cc. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 284 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 291; dd. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 284 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 292; ee. A heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 285 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 290; ff. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 285 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 291; gg. A heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 285 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 292; hh. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 283 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 293; ii. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 284 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 293; jj. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 285 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 293; kk. A heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 286 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 290; 11. A heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 286 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 291; mm. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 286 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 292; nn. A heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 287 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 294; oo. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 288 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 294; pp. a heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 289 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 294; qq. A heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 284 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 299; rr. a heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 295 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 299; ss. A heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 296 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO: 299; tt. A heavy chain variable region having a polypeptide sequence as shown in SEQ ID NO: 297 and a light chain variable region having a polypeptide sequence as shown in SEQ ID NO: 299; or uu. A heavy chain variable region having the polypeptide sequence shown in SEQ ID NO: 298 and a light chain variable region having the polypeptide sequence shown in SEQ ID NO:

299.

4. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, in, The monoclonal antibody or antigen-binding fragment thereof inhibits the enzymatic activity of soluble and / or cell surface CD73, prevents the dimerization of CD73, induces the internalization of CD73, and / or can activate T cells.

5. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, in, The antibody or antigen-binding fragment thereof is chimeric or human or humanized.

6. A bispecific antibody comprising the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 5.

7. An isolated nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof or bispecific antibody according to any one of claims 1 to 6.

8. A vector comprising the isolated nucleic acid according to claim 7.

9. A host cell comprising the vector according to claim 8.

10. A pharmaceutical composition comprising the isolated monoclonal antibody or antigen-binding fragment thereof or bispecific antibody according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier.

11. A method of inhibiting the nucleotidase activity of CD73, preventing CD73 dimerization, inducing internalization of CD73, or treating cancer in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 10.

12. A method for preparing a monoclonal antibody or an antigen-binding fragment thereof or a bispecific antibody as described in any one of claims 1 to 6, comprising culturing a cell comprising a nucleic acid encoding the monoclonal antibody or the antigen-binding fragment or the bispecific antibody under conditions that produce the monoclonal antibody or the antigen-binding fragment or the bispecific antibody, and recovering the antibody or the antigen-binding fragment or the bispecific antibody from the cell or culture.

13. A method for preparing a pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment or bispecific antibody according to any one of claims 1 to 6, comprising combining the monoclonal antibody or antigen-binding fragment or bispecific antibody with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

14. A method for determining the level of CD73 or the ecto-5' nucleotidase activity of CD73 in a subject, the method include: a. obtaining a sample from a subject; b. contacting the sample with the isolated monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 5; and c. determining the level of CD73 or the ecto-5' nucleotidase activity of CD73 in the subject; Preferably, the sample is a tissue sample or a blood sample, wherein the tissue sample is preferably a cancer tissue sample.